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Abstract 
 
Cellular senescence, an irreversible cell cycle arrest induced by a diversity of stimuli, 
has been considered as an innate tumor suppressing mechanism with implications and 
applications in cancer therapy. The senescence phenomenon was first associated with aging 
as Hayflick and colleagues observed that normal human fibroblasts lost their proliferative 
capacity after a finite number of cell divisions in cell culture. Oncogene activation acting to 
potentiate or overstimulate normal growth signaling is a hallmark of cancer. However, in 
“normal” cells oncogene activation does not lead to transformation, but instead provokes 
cellular senescence.  
One characteristic feature of the oncogene induced senescence phenotypes involves 
formation of a unique type of chromatin, known as senescence associated heterochromatin 
foci. Histone modifications have been shown to be part of this chromatin formation. With 
new mass spectrometric technologies developed to analyze histone modifications, specifically 
acetylation and methylation, global histone modification changes in senescent cells were 
studied extensively. A top down proteomic approach to profile all core histones was 
developed and applied to study histone acetylation changes after selective knocking down or 
inhibition of histone deacetylases. This method also allowed us to find decreased acetylation 
levels on all core histone proteins in senescent cells. An alternative method analyzing 
peptides generated by protease digestion provided a quantitative view of most of the 
methylation sites on histone H3. The changed pattern of methylation on Lys 27 and Lys 36 of 
histone H3 in senescent cells, along with hypoacetylation on all core histones, were 
consistent with chromatin in senescent cells adapting a more compact, heterochromatic state. 
The global formation of heterochromatin did not translate to globally suppressed 
levels of transcription and protein translation. A comprehensive quantitative proteomic study 
applying SILAC (stable isotope labelling of amino acids in cell culture) indicated that a large 
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number of proteins were up-regulated (179 of 2206 proteins identified) in senescent cells. 
These proteins were categorized into several functional groups, functioning in RNA 
processing, protein synthesis and energy production. 
Upregulation of proteins involved in oxidative phosphorylation and down regulation 
of proteins involved in glycolysis implied specific alternations of primary metabolism in 
senescent cells. This metabolic shift is the opposite of the well-known „Warburg effect‟ 
which is an observation that most cancer cells predominantly produce energy by a high rate 
of glycolysis followed by lactate fermentation instead of oxidative phosphorylation. The 
metabolic shift detected by large scale proteomics is likely controlled by the regulation of 
pyruvate dehydrogenase (PDH) activity. Data consistent with this hypothesis was collected in 
OIS as both the inactive form of PDH and the cognate kinase (PDK-1) that turns it off 
decreased. Increased activity of PDH drove an increased flux of pyruvate into the TCA cycle 
followed by oxidative phosphorylation instead of lactate production for more efficient ATP 
production during senescence. A combination of limited glycolysis and decreased PDK-1 
expression was shown to trigger the senescence phenotype in normal IMR-90 cells. These 
findings suggest that altered cell metabolism is a central part of the senescence phenotype and 
also contribute to successful execution of the senescence program. How to control the 
molecular switch of cell metabolism could have therapeutic implications in cocktail cancer 
therapy. 
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Chapter 1. Introduction  
 
1.1 Histones and epigenetics 
The fundamental question of how cells with the same genetic DNA sequence 
can differentiate and develop into diverse cell types during the mammalian 
development has led to the postulation that additional information must exist to 
regulate gene functions during the development process beyond the genetic code. This 
concept led to the introduction of “epigenetics” which refers to the heritable 
phenotypes resulting from changes in gene expression without alternations in DNA 
sequence [1]. Studies of the molecular mechanisms of epigenetics have revealed two 
major mechanisms, DNA methylation and chromatin modifications, which work in 
concert to provide stable and inheritable gene expression pattern in higher eukaryotic 
organisms. 
Chromatin structure, composed of the basic building block of nucleosome, is 
the packing of DNA molecules through association with histone proteins. A 
nucleosome usually consists of ~146 bp DNA wrapped around a protein core 
containing two copies of each core histone H2A, H2B, H3 and H4 [2, 3]. 
Nucleosomal DNA is packed further by the addition of histone H1 and other 
nonhistone proteins which link adjacent nucleosomes together, as well as higher order 
folding of the chromatin fiber [2, 3]. This structure works efficiently to pack the long 
linear DNA into cell nucleus.  
Histone proteins are small, basic proteins that are evolutionarily conserved 
throughout different organisms. Each core histone protein can be divided to two 
domains. The C-terminal histone-fold domains of core histones have very similar 
conformations which are important for the assembly of nucleosomes. The N-terminal 
tails which protrude out of the nucleosome cores are less structured and not essential 
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for maintaining the nucleosome structure since removal of these tails by trypsin 
digestion does not diminish the integrity of nucleosomes [4]. Instead, these tails 
contribute to chromatin structure maintenance and regulation in different ways. One 
possible way is they constitute recognition sites for ATP-dependent chromatin 
remoldlers such as NURF [5] perturbing the structure of nucleosomes and facilitating 
binding of transcription factors and also signal activated enzymes which may regulate 
the local chromatin structures. Another way is that these tails are subjected to a large 
pool of combinatorial post-translational modifications (PTMs), including acetylation, 
methylation, phosphorylation, ubiquitination, ADP-ribosylation and sumoylation, 
which may modulate the contact between histones and DNA [6].  
Phosphorylation is a common PTM frequently utilized in cell signalling 
pathways. The best example of phosphorylation on histone tails comes from histone 
H3 Ser 10 which quickly gets phosphorylated when mammalian cells get exposed to 
mitogen or stress [7]. However, how histone phosphorylation affects gene expression 
still needs to be addressed. One possible explanation is that the addition of negatively 
charged phosphate groups may disrupt the electrostatic interaction between positively 
charged histone proteins and negatively charged DNA molecules.   
Histone acetylation occurs at lysine residues, thereby neutralizing the positive 
charge of the histone tails and decreasing their affinity for negatively charged DNA 
[8]. Consequently, the altered nucleosomal conformation can increase the 
accessibility of transcription factors to chromatin templates [9]. Consistent with these 
evidence, acetylated core histones were shown to preferentially associate with 
transcriptionally active chromatin [10]. The direct connection between histone 
acetylation and transcription came from the evidence that yeast cells with mutated 
lysine residuals which are supposed to be acetylated showed largely altered gene 
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expression patterns and mammalian cells treated with histone deacetylase inhibitors 
showed increased expression of a variety of genes [8, 11]. However, these mutations 
or drug treatments broadly affected chromatin structures, and are also likely affect 
other cellular targets. Further understanding of the relation between histone 
acetylation and transcription was provided by increasing knowledge about histone 
acetyltransferases and histone deacetylases. Many proteins previously identified as 
transcription regulators were found to possess intrinsic acetyltransferase activities 
[12].  
Histones, especially H3 and H4, are methylated at a number of lysine and 
arginine residues, mostly on Lys 4, Lys 9, Lys 27, Lys 36 and Lys 79 on H3 and Lys 
20 on H4. These modification marks have been proved to be very important in cell 
development [13, 14, 15]. In addition, these residues can be mono-, di- and tri-
methylated. These diverse modification states provide great potential functional 
diversity and they are created by a number of histone methyltransferases. For example, 
Suv39H1 specifically targets histone H3 at Lysine 9 [16]. Methylation is more stable 
than acetylation and it had been considered as a permanent mark for years until the 
recent discoveries of the demethylating enzymes suggesting that histone methylation 
is reversible [17, 18]. The activity and regulation of histone demethylases has been 
shown to be linked to cell development and disease states [19]. 
Different modifications on the same or different histone tails may be 
interdependent, but clearly generate hundreds of distinct combinations of protein 
forms suggesting a "histone code" that significantly extends the information potential 
of the genetic code [20]. A key question in the histone code hypothesis is how each
 
modification or “code” is recognized and utilized to translate to gene regulation. One 
possibility
 
is that once a histone code is generated, it serves as a
 
signal for the binding 
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of a downstream regulatory protein or a protein complex,
 
which in turn specifies the 
function of the code. The findings
 
that the bromodomain of TAFII250 specifically 
binds to acetylated
 
H4 tails and that the chromodomain of HP1 and polycomb proteins 
differentially
 
recognizes K9- versus K27-methylated H3 tails provide evidence
 
for this 
proposal [21, 22, 23]. 
Other than histone modifications, the fact that in higher organisms each core 
histone subtype, except histone H4, is represented by a family of genes encoding 
multiple primary-sequence variants increases the complexity of histone forms even 
more. These histone variants are thought to replace their counterparts at specific 
positions in the genome for specialized functions [24]. For example, the nucleosomes 
at the centromeres contain the H3 variant Cse4/CENP-A, and they are believed to 
perform centromere-specific functions [24]. H2A.X is an H2A variant in human cells 
which is rapidly phosphorylated in response to DNA damage and functions to mark 
the damaged areas as well as to recruit DNA damage repair complexes [25, 26]. 
As mentioned earlier, DNA methylation is another mechanism associated with 
epigenetics. DNA methylation occurs at the C5 position of cytosine residues that are 
in the context of CpG dinucleotides with S-adenosyl-methionine as the methyl donor. 
It has been estimated that nearly 80% of all CpG dinucleotides are methylated in the 
mammalian genome [27]. The unmethylated CpG residues are mostly located in the 
promoter regions of constitutively active genes. DNA methylation and histone 
modifications are highly coordinated in the cell nucleus. DNA methylation 
functioning as transcription silencing is in part mediated by recruitment of HDACs 
through the methyl-DNA binding motifs of components of several HDAC-containing 
complexes [28, 29]. Direct functional links between DNA and histone methylation 
have been uncovered by genetic evidence indicating that H3 Lys9 methylation is a 
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prerequisite for DNA methylation [30, 31]. On the other hand, examples of ablation of 
DNA methylation affecting H3 methylation and other histone modifications have also 
been found in Arabidopsis and human cells [32, 33]. It suggests that DNA 
methylation and histone methylation are mutually reinforcing each other, and both are 
required for stable and long-term epigenetic silencing. 
Over the last decade, epigenetic disorders have been suggested to be 
associated with some disease states, including cancer [34, 35], neuropsychiatric 
disorders [27], and autoimmune
 
diseases [36]. Several epigenetic therapies are 
currently being studied in clinical trials or have already been
 
approved for specific 
cancer types [37]. For example, different HDAC inhibitors are being used 
intravenously or orally in several phase I and II clinical trials. However, our 
understanding of the role of epigenetic abnormalities in
 
disease processes is still in its 
infancy. The primary goals
 
in the future will include improving our understanding
 
of 
the interactions between epigenetic mechanisms, gene expression
 
and the environment. 
By decreasing the threat of epigenetic instability
 
that leads to disease and by 
correcting epigenetic abnormalities
 
that predispose to diseases later in life, the 
promise for epigenetic
 
therapies as an essential treatment option will be fulfilled. 
 
1.2 Quantitative proteomics and systems biology 
Systems biology emerges as a discipline trying to understand a biological 
system‟s structure and dynamics largely due to great progress in recent technology 
development, especially in genome sequencing and high-throughput measurements 
that have enabled researchers to collect comprehensive data to assess the performance 
of complex biological systems. Basic scientific research using systems biology helps 
researchers accumulate fundamental knowledge about the normal and pathological 
  6 
states of cells which in turn can help predict and prevent diseases. With the continuing 
development of new technologies, systems biology will largely enhance the scale, 
efficiency and accuracy of measurements made on various cell states. 
Proteomics has recently come to the forefront of systems biology field. The 
ultimate goal of proteomic research is to understand the expression, function and 
dynamics of proteins on a global level from different biological conditions. A variety 
of proteomic approaches have been applied to study the entire complement of proteins 
produced by an organism, organelle or a single cell line, including protein microarrays 
[38], large scale two hybrid approaches [39] and high-throughput protein 
crystallization [40]. However, mass spectrometry based proteomic strategies have 
become the method of choice for in-depth analysis of the protein components in a 
biological system due to their ability to generate high-content qualitative and 
quantitative information about a proteome [41].  
Mass spectrometric measurements are carried out in gas phase on analytes 
ionized by either electrospray ionization (ESI) or matrix-assisted laser 
desorption/ionization (MALDI). Both of these methods prevent or minimize 
fragmentation of macromolecules like peptides and proteins during the ionization 
process. Ions are analyzed by different types of mass spectrometers which are very 
different in design and performance [42].  
  The major challenges for proteomic studies are the complexity and 
substantial dynamic range of all proteins in a proteome. The proteome is much more 
complicated than an organism‟s genome and as one move from genes to transcripts 
and proteins, there is increasing variation. One important reason is that the product of 
one gene can be transformed to a family of gene products [43], i.e., one gene can 
produce multiple mature mRNAs via alternative splicing and other mechanisms. At 
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the protein level, polymorphisms, nucleotide variations, proteolytic cleavage as well 
as post-translational modifications, combinatorially add a large number of forms to a 
protein product. On top of this biological complexity, another important factor is the 
dynamic range of proteins, since one cell can contain between one and more than 
100,000 copies of a single protein [44]. In serum, it is dominated by a few highly 
abundant proteins resulting in a dynamic range up to ten orders of magnitude [45]. 
Finally, the proteome of an organism is dynamic and changes with time and 
environment [43]. 
Before introducing the analytes into a mass spectrometer, a number of 
analytical methods are used to reduce sample complexity. As an orthogonal and 
highly resolving separation technique, two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE), introduced more than three decades ago still plays an 
important role in many proteomic analysis. However, 2D-PAGE cannot be coupled 
directly with MS to achieve a fast multi-dimensional protein separation and 
identification platform. Hence, multi-dimensional liquid phase based separation 
approaches using different chromatographic and electrophoretic techniques have been 
developed as complementary methodologies. The use of multi-modular combinations 
of isoelectric focusing (IEF), HPLC, chromatofocusing (CF), capillary electrophoresis 
(CE) as well as combinations of different HPLC modes provides plentiful options for 
the separation of protein mixtures [46]. 
The two complementary mass spectral approaches to proteomics are termed 
“bottom up” and “top down” [47, 48]. Bottom up analysis usually requires chemical 
reactions or proteases to cut pre-fractionated intact proteins or a whole protein 
mixture after specific amino acid residues. The resulting peptides are most often 
further separated by reverse phase liquid chromatography coupled to a mass 
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spectrometer. The mass spectrometer can be instructed to first measure the masses of 
all the peptides eluting at any given time from the chromatography column, and then 
select some peptide ions in turn for fragmentation. It allows ions of a particular mass 
pass through to a “collision cell,” where the peptide ions' kinetic energy is increased 
and they collide with inert gas molecules to break peptide bonds apart with sufficient 
energy. The resulting spectrum, also known as a tandem, or “MS/MS,” spectrum, 
generally contains several adjacent fragments that spell out a partial sequence of the 
peptide analyzed. These fragments are then compared to fragments calculated from all 
peptides in protein databases to retrieve a list of observed peptides and thereby a list 
of identified proteins. This strategy has been proven to work well for high-throughput 
identification of thousands of proteins from a given sample [49, 50], but it has 
significant limitations. The relative low sequence coverage (usually between 5% and 
50%) restricts the possibility of detecting and charaterizing any PTMs or biological 
variations, let alone a combination of PTMs and variations. 
The top down strategy omits the digestion step, analyzing intact proteins 
directly in a mass spectrometer. It provides high sequence coverage (routinely 100%) 
and full protein characterization to capture biological information. In its early days 
top down mass spectrometry focused on high resolution mass measurement of a single 
protein followed by isolation and fragmentation within the mass spectrometer [51]. 
Since then it has evolved from analyzing single protein targets to small subproteome, 
such as histone proteins [52, 53, 54, 55, 56], further to studying complex mixtures 
[57]. The accurate mass measurement of both MS and MS/MS allows extensive 
characterization of protein primary structures potentially harboring a variety of 
biological events, such as alternative splicing, single amino acid variation and PTMs, 
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that create mass differences between mature protein products and the predicted 
sequences of their corresponding genes. 
An important breakthrough in mass spectrometry based high-throughput 
proteomics is protein quantitation since a protein‟s expression level is highly related 
to its functions in a complex cellular environment. MS is an exquisitely sensitive 
method identifying proteins; however, it is not readily quantitative. The MS peak 
intensity of a peptide depends linearly on the concentration of the peptide; however, 
different peptides have different propensities for ionization. Therefore, two different 
peptides with equimolar amounts may display substantially different intensities in a 
mass spectrum. Hence, a lot of quantitative techniques are based on modifying one of 
the samples with a stable isotope, which changes the molecular mass but not the 
chemical structure. Thus these peptide pairs have the same chromatographic and mass 
spectrometric behaviour. Quantitative differences are then measured directly as the 
different peak areas of the two peptides in the mixed sample. Two commonly used 
approaches to labelling peptides with stable isotopes are: chemically incorporating the 
mass tag, such as a biotin tag with a linker region with either zero or eight deuterium 
atoms (ICAT) [58], usually by reacting with cysteines; or, metabolic incorporation, 
where labelling of the proteins is achieved by growing cells in a medium enriched in 
stable isotope-containing precursors, such as SILAC, for stable isotope labeling by 
amino acids in cell culture [59, 60].  Also, other quantitative approaches without 
isotopic labelling have been developed [61, 62]. 
Much effort has been spent on applying quantitative proteomics for protein 
profiling looking for changes in protein expression, protein-protein or protein-DNA 
interactions, post-translational modifications and the constituents of cellular 
organelles. For example, ICAT has been utilized to perform quantitative analysis of 
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differential protein expression in complex biological samples such as cancer cells and 
tissues of human cancer patients [63, 64]. SILAC has been successfully adapted to 
label proteins in living animals [65]. It provides a useful tool to quantitatively 
compare proteomes from knockout mice and thereby determine protein functions 
under complex in vivo conditions.  
Although there are many technical challenges remaining for mass 
spectrometry based proteomics, it has been delivering useful information to life 
science research. Combining with other systems biology strategies, such as 
microarray measurement, it will give us unprecedented insight into how cells make 
decisions and it will likely serve as a cornerstone of systems biology.   
 
1.3 Cellular senescence 
The senescence phenomenon was first associated with aging in the early 1960s 
as Hayflick and Moorhead established the concept that primary cells isolated from 
tissue and grown in culture reach a finite number of cell divisions [66]. When these 
cells reached their replicative limit, they were termed senescent cells and viewed as 
aged cells. The limit has become known as “Hayflick limit” and this senescence 
phenomenon has been termed as replicative senescence. 
The concept of replicative senescence refers to cells capable of mitotic 
division that have undergone cell cycle arrest as a result of telomere attrition. 
Telomeres are regions of repetitive DNA sequences (TTAGGG in vertebrates) and 
associated proteins that cap and stabilize an end of a chromosome, preventing end 
fusions and genomic instability. Telomere attrition occurs with each round of cell 
division because of incomplete DNA replication associated with the so called “end-
replication problem”. It states that replicated linear DNA would be shorter than its 
template because of the inability of DNA polymerase to fully replicate the ends of 
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linear DNA. Telomerase, the enzyme that can synthesize telomeric DNA de novo, is 
not expressed by most human cells. Experimental evidence demonstrated that the total 
amount of telomeric DNA was reduced during the serial proliferation of human 
diploid fibroblast (HDF) cells, with the average telomere length decreasing by 50 base 
pairs per population doubling [67]. It was afterwards proposed that the exit of HDFs 
from the cell cycle was due to telomere shortening [68]. 
The discovery of telomere erosion appeared to provide a mechanism to 
explain the limited replicative capacity of proliferating cells and aging. However, it 
soon became evident that processes which appeared to be more complex were at work. 
It was observed that events inducing DNA damage also resulted in cell cycle arrest 
and the senescence-like phenotypes could be induced by multiple stimuli, including 
oxidative stress, excess glucose, and other environmental stresses [69, 70, 71, 72]. 
Surprisingly, in contrast to the fact that oncogenic ras can transform most immortal 
rodent cells into tumorigenic state, expression of oncogenic ras in primary human or 
rodent cells resulted in cell cycle arrest and senescence phenotypes [73]. Subsequently, 
expression of a variety of oncogenes, including BRAF (74), E2F1 (75) and MYC (76), 
has been shown to be able to drive a burst of cell hyperproliferation followed by a 
proliferation slow down and eventually cell growth arrest. These stimuli drive 
senescence only after a few cell divisions and without telomere shortening.  
Despite the diverse triggers of cellular senescence, senescent cells share some 
common features, including cell cycle arrest, altered gene expression, altered 
responsiveness to apoptosis stimuli, changed cell morphology and characteristic 
senescence associated β-galactosidase activity. A hallmark of senescent cells is their 
ability to undergo notable morphologic transformations. The most obvious changes in 
culture that accompany the onset of senescence are the remarkable increase in cell 
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size and flattened or thin cytoplasmic appearance. Also, the cytoplasm becomes 
highly vacuolated, and the nucleus frequently becomes centrally located within the 
cytoplasm [77]. The incapacity to replicate and lack of sensitivity to physiologic 
mitogenic stimuli are other hallmarks of senescence. HDFs in early passages 
proliferate in response to a variety of mitogenic stimuli, such as EGF, TNF-α, and IL-
1. However, late passage cells which have reached senescence states fail to respond to 
these stimuli, even though they maintain normal numbers of receptors and normal 
binding affinity [78]. Cellular senescence entails many changes in gene expression, 
only some of which are involved in the growth arrest, including p53, p21CIP1 (p21), 
p16INK4a (p16), p38 mitogen-activated protein kinase (p38MAPK) and the 
retinoblastoma protein (Rb). Senescent fibroblasts overexpress many secreted proteins, 
such as metalloproteinases, inflammatory cytokines, and growth factors. These 
secreted factors can destroy the local tissue structure, attract cells that cause 
inflammation, and stimulate neighboring cells to grow [79]. 
Detailed studies at the molecular level have revealed two major pathways for 
the induction of cellular senescence. These pathways are governed by the gatekeeper 
tumor suppressor proteins p53 and pRB. p53 plays a pivotal role in regulating several 
aspects of cellular function, including control of cell growth, DNA damage response 
and apoptosis [80]. The fact that loss of p53 function delays or abrogates replicative 
senescence [81] raised the possibility that dysfunctional telomeres resemble damaged 
DNA and trigger p53 mediated DNA damage responses. Later evidence showed that 
senescent human fibroblasts indeed displayed molecular markers of DNA double-
strand breaks and dysfunctional telomeres directly contributed to the DNA damage 
responses [82]. Further studies demonstrated that the senescence response to 
dysfunctional telomeres required the integrity of p53 pathway [83]. The p53 pathway 
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is also required by oncogene induced senescence as disruption of p53 is sufficient to 
prevent oncogenic ras induced cell cycle arrest in rodent cells [73]. Also, inactivation 
of a p53 target protein, p21, an inhibitor to cell cycle progression, causes cells to 
bypass telomere dependent replicative senescence [84].  
Although p53 inactivation bypasses senescence in some cells, it fails to do so 
in others [73, 85]. It suggests that alternative pathways are functional in regulating the 
senescence response. It turns out another inhibitor to cell cycle progression, p16, 
plays important roles in the induction of senescence [86, 87, 88].  p16 is a positive 
regulator of pRB and induced by a variety of stimuli, including overexpression of 
oncogenes [89]. Rb is a cell-cycle regulator functioning in controlling cell cycle 
progression from G0 and G1 to S phase [90]. Cell cycle progression is dependent on 
hyperphosphorylation of Rb by cyclin-dependent kinases (CDKs) associated with 
cyclins to allow transcription of genes involved in G1- to S-phase transition. p16, 
elevated and accumulated in senescent cells, inhibits CDKs and the phosphorylation 
of Rb. Senescent cells develop dense foci of heterochromatin which coincide with 
pRB dependent heterochromatin repression of E2F responsive genes [91]. These foci, 
termed as senescence associated heterochromatin foci, consist of several chromatin 
proteins, including the heterochromatin markers K9-methylated histones H3 and HP1, 
the histone macroH2A variant, and HMGA proteins [92]. These foci appear 
predominantly in response to p16/Rb-dependent senescence rather than by p53 
activation. 
Cellular senescence induced by multiple stimuli ultimately engages either p53 
or pRB pathway. However, the p53 and pRB pathways are not independent. In fact, 
they interact at multiple levels [93, 94]. One example is that, p21, which is induced by 
p53, inhibits CDKs that inactivate pRB, and pRB in turn binds MDM2, preventing it 
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from facilitating p53 degradation. Thus, senescence is delayed or abrogated not only 
when either p53 or pRB is inactivated, but also when key components of either 
pathway are inactivated. Potential cancer cells must lose p53 and/or pRB function in 
order to overcome the proliferative barrier imposed by cellular senescence. This can 
arise by mutation or epigenetic silencing of one or several key components of the 
pathways. 
There has been increasing evidence that links cellular senescence and tumor 
suppression derived from both cell culture, and intact organisms. The replicative 
lifespan of fibroblasts is extended by inactivation of p53 or Rb by viral oncoproteins 
[95]. Cells derived from mice in which genes encoding p53 or INK4a proteins are 
inactivated in the germline fail to senesce in response to multiple stimuli. In all cases, 
the animals develop cancer at an early age [96]. By contrast, a genetic manipulation 
that causes premature senescence of mammary epithelial cells suppresses the 
development of breast cancer in young mice exposed to the mouse mammary tumor 
virus [97]. Also, in evaluating the relative contribution of apoptosis and senescence to 
tumor suppression in murine models of tumorigenesis, the senescence pathway was 
found to play a more significant role than apoptosis [98, 99]. Although cancer cells 
have to bypass cellular senescence, they still retain the capacity to undergo 
senescence. Much evidence suggests that cancer cells exposed to sublethal doses of 
anticancer drugs will senesce rather than become apoptotic. Hence, cellular 
senescence is increasingly recognized as an important approach in cancer therapy 
with radiation and several agents, including doxorubicin (Adriamycin), camptothecin, 
cisplatin, and daunomycin, inducing cellular senescence in cancer cells both in vitro 
and in vivo [100, 101, 102, 103]. 
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Chapter 2. Top down mass spectral profiling of human histone proteins 
 
The information and contents of this chapter were largely adapted from this published 
article: Li, M.; Jiang, L.; Kelleher, N. L., Global histone profiling by LC-FTMS after 
inhibition and knockdown of deacetylases in human cells. J. Chromatogr. B 2009, 
877, (30), 3885-3892. 
 
2.1 Introduction 
In eukaryotic cells, genetic information is highly organized into chromatin in 
the cell nucleus. The fundamental building block of chromatin is the nucleosome, 
which is composed of an octamer of core histone proteins, including H2A, H2B, H3 
and H4, wrapped around by 146 base pairs of DNA [1]. The local conformation of 
chromatin influences the access of chromatin-associated proteins to DNA and hence 
has important functions in gene regulation. Core histone proteins are evolutionarily 
conserved and the flexible amino-terminal tails are subject to extensive post-
translational modifications, including methylation, acetylation, phosphorylation, 
ubiquitination, ADP-ribosylation and sumoylation [1]. Specific modifications of the 
histone tails modulate interaction affinities of chromatin-associated proteins and 
transcription factors. Different modifications on the same or different histone tails 
may be interdependent, but clearly generate hundreds of distinct combinations of 
protein forms [2, 3] suggesting a "histone code" that significantly extends the 
information potential of the genetic code [4]. 
Most frequently, histone modifications are analyzed by using highly specific 
antibodies against specific histone modifications at particular amino acids. However, 
despite being highly sensitive, these methods are not informative about the global 
state of chromatin in cells and can give false readings from neighbouring 
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modifications affecting antibody binding [5, 6, 7].
 
Recently, the coupling of high 
performance liquid chromatography and mass spectrometry (LC-MS) has enabled the 
detection of multiple post-translational modifications occurring on histone H2A and 
H4 [8, 9]. More detailed information associated to the location of a specific 
modification, if required, can be obtained by tandem mass spectrometry (MS/MS). 
Both top down [10, 11, 12, 13, 14] and bottom up [15, 16, 17] MS approaches have 
been successful in generating a comprehensive map of isolated histone PTMs and 
hundreds of specific combinations of PTMs on the most heavily modified histone, H3 
[3]. 
Histone acetylation is associated with transcriptional activation [18]. 
Additionally, acetylation of core histones has been correlated with other genome 
functions, including chromatin assembly, DNA repair and recombination [19]. The 
dynamic equilibrium of histone acetylation levels is achieved by histone 
acetyltransferases (HATs), such as p300, CBP and P/CAF, and histone deacetylases 
(HDACs). HDACs often function in concert with other proteins to form multiprotein 
complexes (e.g., NuRD [20], N-CoR [21], SMRT [22], and Sin3 [19]) recruited to 
specific chromatin loci to remove acetyl groups from histones and in turn suppress 
gene transcription. Overexpressed or sustained HDAC activity, occurring in some 
cancer cells [23, 24], results in deacetylation of the histone tails (a.k.a. histone 
hypoacetylation).  
HDAC inhibitors were originally discovered based on their ability to inhibit 
growth of transformed cells.  HDAC inhibitor molecules induce transformed cell 
arrest and even cell death with only a minor fraction of genes being deregulated [25]. 
To date, there are five distinct classes of HDACi according to their chemical 
structures [26] and various HDACi from several chemical classes have already 
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advanced into clinical trials. However, the mechanisms by which HDAC inhibitors 
induce cell
 
cycle arrest and cell death are not well elucidated. Key advancement in the 
development of potent HDAC inhibitors, however, is dependent on appropriate assays 
that require rapid screening applications with high sensitivity, selectivity and cost-
effectiveness. Traditional assays for the in vitro determination of HDAC activity are 
based on the incubation of the purified enzyme or cell nuclear extracts with acetate-
radiolabeled histones from chicken reticulocytes or cultured cells previously fed with 
[
3
H]acetyl-CoA [27, 28]. Currently, non-isotopic in vitro assays with fluorescent 
substrates and purified enzymes have well approached the suitability of high 
throughput screening. 
We have used top down mass spectrometry to study the global profile of 
human histones, by an online LC-MS method using >10
2
 better mass resolving power 
than prior LC-MS histone assays [8, 9]. This method provides a global view of core 
histones from as few as 10
5
 cells. This LC-MS method is also suitable for screening of 
HDAC/HAT inhibitors and efficiently provides a gene-specific snapshot of each 
histone in the context of global chromatin. 
 
2.2 Experimental procedures 
Cell culture and reagents. Hela S3 cells and 293T cells were maintained in 
Dulbecco‟s modified Eagle‟s medium (DMEM) with 4.5 g/L glucose containing 10% 
fetal bovine serum at 37
o
C with 5% CO2. Reagents for siRNA were ordered from 
Dharmacon and prepared according to the vendor‟s instructions. Transfection with 
control siRNA, HDAC1-specific or HDAC2-specific siRNA (SMARTPool) was 
performed by using DharmaFECT (Dharmacon). Sodium butyrate, TSA, apicidin and 
valproic acid and Anacardic acid were purchased from Sigma. 
  25 
Lentivirus-delivered RNAi. shRNAs for human HDAC3 constructed in pLKO.1-Puro 
vectors were purchased from Sigma (Mission shRNA) and contained 5 constructs 
with different target sequences, all of which were packaged for viral production and 
infection, and tested for target knockdown. shRNA with scrambled sequence was 
used for a negative control. For viral packaging, pLKOshRNA, pCMV-dR8.91 and 
pCMV-VSV-G were co-transfected into 293T cells using Fugene 6 (Roche). Media 
containing viruses were collected 48 h after transfection. Hela S3 cells were infected 
with the viruses in the presence of polybrene (8 mg/mL) for 24 h, and then subjected 
to selection by 2 µg/mL puromycin for 5 days prior to further analysis. 
Treatment with HDAC and HAT inhibitors. HeLa S3 cells and 293T cells were 
treated by 10 mM sodium butyrate and 1 µM TSA for 4 h, respectively. 293T cells 
were treated by 2.5 µM apicidin or 5 mM valproic acid  for 4 h. HAT inhibitor, 
anacardic acid was used to treat HeLa S3 cells and 293T cells for 24 h in a final 
concentration of 15 µM. All control cells were treated by the same volume of DMSO. 
Histone purification. Mammalian histones were purified as described below.  Briefly, 
cells were scraped from plates in nucleus isolation buffer (15 mM Tris-HCl; pH 7.5, 
60 mM KCl, 11 mM CaCl2, 5 mM NaCl, 5 mM MgCl2, 250 mM sucrose, 1 mM 
dithiothreitol, 5 nM microcystin-LR, 500 μM 4-(2-aminoethyl) benzenesulfonyl 
fluoride, 10 mM sodium butyrate and 0.3% NP-40). Nuclei were gently pelleted by 
centrifugation and washed with nucleus isolation buffer (same as mentioned above, 
but without NP-40). Histones were acid extracted with 0.4 N H2SO4 for 30 min. and 
precipitated with 20% trichloroacetic acid (TCA) overnight, followed by washes with 
cold acetone containing 0.1% HCl and then pure acetone. Before further separation by 
RPLC, the sample was oxidized by
 
incubating at room temperature in 3% (v/v) formic 
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acid and 3% H2O2 (v/v) for
 
4 h [26]. Yeast histones were purified and analyzed as 
described previously [27]. 
Western blotting. Protein concentrations of cell lysates were measured by the 
Bradford method. Approximately 20-30 µg of protein is loaded onto 12% SDS-PAGE 
and transferred to a PVDF membrane. The membranes were probed with primary 
antibodies against HDAC1 (1:3000), HDAC2 (1:3000) (Upstate Biotechnology, Lake 
Placid, NY), HDAC3 (1:2000) and GAPDH (1:5000) (Santa Cruz) in 0.05% Tween 
20/PBS and then with an HRP-labeled secondary
 
antibody (1:3000; Santa Cruz). 
Proteins were visualized by chemiluminescence with ECL Western blotting detection 
reagents (Pierce). 
Online LC-MS. All LC-MS experiments were performed on an LTQ-FT mass 
spectrometer operating at 7 Tesla (Thermo Fisher Scientific, San Jose, CA). Histones 
were separated by reverse-phase HPLC (Alltech Vydac TP C18 column, 1.0 mm i.d., 
250 mm, Nicholasville, KY) at a constant flow rate of 50 µL/min. Mobile phases were 
(A) 0.05% trifluoroacetic acid (TFA) in water and (B) 0.05% trifluoroacetic acid in 
acetonitrile. Using 0.05% TFA increased separation power and, with the lower 
concentration, reduced the presence of TFA adducts. Phase B increased from 0 to 
30% in 20 min. and from 30% to 60% in 100 min. Between each run, the column was 
washed by 3 gradients from 0% B to 100% B and then equilibrated at 0% B for 25 
min. To minimize adduction of phosphate anions and ion-pairing reagents, a setting of 
20 V was used for mild ion activation in the ESI source. The LTQ-FT method 
consisted of two scan events. The initial event performed a full scan in the ion trap. 
The second segment was used for a broadband high-resolution scan in the trapped ion 
cell of the Fourier-Transform (FTMS) portion of the instrument with AGC setting at 
1,000,000 ions and resolution of 100,000 at m/z 400. The monoisotopic mass of each 
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peak was calculated by using the Xtract algorithm for mass assignment of FT-ICR 
MS data. 
 
2.3 Results 
HPLC separation and MS detection of intact histones. Top down mass spectrometry 
has been successfully applied to the identification and characterization of histone 
forms with pre-purified histone fractions with large sample requirements [10, 11, 12, 
13, 14]. In order to study the global histone status from samples with limited 
resources, a more sensitive method is needed. Several modifications have been made 
to improve the chromatography based on previous literature (experimental 
procedures). Particularly, oxidation of samples
 
before RPLC separation converted 
methionine to methionine sulfone and helped to resolve each histone type into an 
individual
 
chromatographic peak (Figure 2.1A). All the FTMS spectra during the 
elution time of each chromatographic peak were summed together to generate the 
averaged broadband spectrum of each histone (Figure 2.1B). To test the analytic 
detection limit of this method, histones were purified from populations of 10
6
, 10
5 
or 
5×10
4
 293T cells which were trypsinzed and counted via a hemocytometer and 
analyzed by LC-FTMS. Figure 2.2 displays the total ion chromatograms and spectra 
of histone H4 from each run. While higher cell counts did transfer to spectra with a 
higher signal to noise ratio, 5×10
4
 cells were sufficient to generate histone profiles 
showing modified forms and variants of H2A, H2B and H4. Hence this LC-FTMS 
method was able to record histone PTM profiles from a number of cells readily 
workable in diverse applications; this provides the possibility to study histone profiles 
from clinical samples and even whole tissues, as histone extraction works clearly in 
such cases [29]. Further improvements in sensitivity can easily be achieved by 
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targeting narrow m/z ranges for particular histones but handling <<10
4
 cells is 
challenging without an altogether different type of sample preparation. 
Combined with previous data acquired from extensive MS/MS for each peak 
in the spectra [10, 11, 12, 15], we were able to distinguish different modified histone 
forms or variants of H2A, H2B and H4 from HeLa S3 and 293T cells using intact 
protein masses alone (Figure 2.1B). Since histone H3 has a more complicated 
spectrum, which form each peak represents is not completely elucidated though much 
is known about the composition of intact H3 [3, 14]. The relative ratios obtained from
 
intact histone forms of at least moderate abundance (i.e., specific histone forms 
present at >10% relative abundance in global chromatin) did not change appreciably 
(i.e., less than 10% variation) from 3 repeated samplings of untreated cells (e.g., 
Figure 2.3 B), consistent with our prior work on histone H4 [30].  
Use of FTMS provides ~100,000 resolving power to clearly distinguish 
histone forms from one to another, including each histone isotopic distribution; for 
example, the most abundant form of human histone H4 obtained from our LC-FTMS 
method has been shown to have an N-terminal acetylation and two methylations on 
K20 previously [31]. The experimental monoisotopic mass (11331.42 Da) matched 
well with the theoretical neutral mass (11331.37 Da) with less than 5 ppm error 
(Figure 2.4) and these performance metrics were retained even at low sample amount 
(vide infra).  
Human epithelial carcinoma cell line HeLa S3 and embryonic 293 T cells 
derived from human kidney showed similar histone profiles of H2A, H3 and H4 
(Figures 2.1 and Figure 2.8). Histone H2B from these two cell lines showed 
significant deviation in expression of different isoforms (Figure 2.3). The most 
abundant H2B isoform in HeLa S3 cells is H2B.A (13830.50 Da). However, in 293T 
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cells the most abundant form is either H2B.Q or H2B.F or a mixture which have the 
same mass (13844.51 Da). To calculate the relative abundance of these different H2B 
isoforms, H2B.E/T, H2B.A and H2BQ/F, we measured the relative MS intensity of 
the most abundant isotopic peak of each form from 3 different samples on different 
days. The relative percentage of each peak was calculated and plotted in Figure 2.3B. 
Most of the H2B forms observed here differ only by one or two amino acids. The 
differences including alanine changing to serine or threonine which could be potential 
phosphorylation sites are difficult to be observed by bottom up approach. Since the 
specific functions of different histone variants in cells are still not fully understood, 
LC-MS profiling of histones with high resolution can shed a light on finding histone 
variants expression variation from different cellular events. 
 
Knockdown of selected HDACs. With an ability to produce clear PTM profiles from 
few cells, HDAC1 and HDAC2 were knocked down separately by specific siRNA in 
293T cells at ~50% and ~70% respectively (Figure 2.5A). The global histone 
acetylation levels were not affected significantly (Figure 2.5B). Since HDAC1 and 
HDAC2 are usually found to interact with each other in a protein complex [20, 32], 
both of them were knocked down simultaneously in 293T cells; no evidence for 
significant hyperacetylation of global histone was observed by LC-FTMS (Figure 2.5). 
HDAC3 was knocked down by ~70% using shRNA in HeLa S3 cells (Figure 2.6A) 
and also global histone acetylation as profiled here was not significantly affected 
(Figure 2.6B and data not shown).  
 
Profiling the effects of HDAC and HAT inhibition. Upon treatment of HeLa S3 cells 
and 293T cells using either 10 mM sodium butyrate or 1 µM Trichostatin (TSA) for 4 
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h, all core histones displayed hyperacetylation profiles (Figure 2.7 and 2.8). TSA and 
sodium butyrate are both HDAC inhibitors with a broad spectrum of activity against 
class I and II HDACs, but not the SIR2 family [33]. When class I and II HDACs were 
inhibited, HATs act to hyperacetylate core histones. Two HDAC class-I-selective 
inhibitors, Valproic acid and apicidin [34], caused comparable level of histone 
hyperacetylation as the TSA treatment of 293T cells (Figure 2.9 and data not shown).  
When HAT activity was inhibited by anacardic acid which is a potent, non-
competitive inhibitor of p300 and PCAF [35], a decrease of histone acetylation level 
was observed on H2A and H2B (Figure 2.10). The results indicate under normal 
conditions global histone acetylation is controlled by both the activity of HDACs and 
HATs.  
Cell lines differ in response to HDAC inhibitors. Comparing histone acetylation 
levels on H4 from populations of asynchronous control HeLa S3 and 293T cells, the 
data show somewhat greater levels of baseline acetylation in 293T cells where up to 4 
internal acetylations can be observed from asynchronous cells (Figure 2.11A, bottom 
left). This may correlate with global HDAC activity in different cell lines. When we 
inhibited HDAC activities by using 1 µM TSA, increases in acetylation levels were 
observed in both cell lines. However, H4 from 293T cells showed far more 
hyperacetylation upon the same TSA treatment (Figure 2.11B). Assuming TSA has 
the same permeability into the two cell lines, it suggests that global HDAC activity is 
lower or global HAT activity is higher in 293T cells vs. HeLa. In order to rule out the 
possibility that two cell lines have different permeabilities for TSA, we also compared 
the data using other non-specific HDAC inhibitors, for instance, sodium butyrate, and 
the same response was observed. This difference of cell line in response to HDACi 
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may be caused by upregulation of HDAC protein expression or increased global 
HDAC activity in some cancer cells. 
 
2.4 Discussion  
Histones have multiple gene family members and variants, all of which 
potentially serve specific biological functions. Most of the protein forms in each gene 
family are highly conserved. In some cases, they differ by as little as a single amino 
acid change. It is very difficult to distinguish these isoforms using antibody based 
approaches due to its limited specificity or bottom up mass spectrometry due to its 
relative low sequence coverage. Profiling with LC-MS using the top down approach 
provides a global perspective on chromatin and a method to distinguish very closely 
related histone species. For example, it has been shown that H2A variants expression 
ratios differ between chronic lymphocytic leukemia patients and normal volunteers 
[9]. In our approach, highly accurate intact mass measurement form online profiling 
and extensive offline fragmentation provides high confidence for protein 
identification. This „intact mass tag‟ concept has also been used in other studies [36, 
37]. 
Histone acetyltransferases and deacetylases can be targeted to promoters to 
activate or repress gene transcription. In yeast, HATs and HDACs not only function 
in a loci specific manner but also at a global level throughout the genome [38].  Top 
down mass spectrometry has shown that knocking out rpd3, one of the HDAC genes 
in yeast, caused hyperacetylation on histone H3 and H4 (unpublished data from the 
Kelleher group). In mammalian cells, HDAC1, HDAC2, HDAC3 and HDAC8 belong 
to class I which is homologous to yeast RPD3. In sharp contrast to yeast, knockdown 
of individual class I HDAC protein in human does not affect global histone 
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acetylation levels. Though global histone acetylation is not changed, HDACs‟ 
function of repressing tumor suppressor genes is abolished once they are depleted or 
knocked down [39, 40, 41]. It is likely that only a small number of histones at specific 
chromatin regions are hyperacetylated once one HDAC is knocked down. These 
subtle changes may not be detected by our LC-FTMS approach which targets histone 
modification at the global level. Specific HDACs are recruited to specific gene loci 
and all or some of the different HDACs may be able to compensate depleted HDACs 
to maintain global histone acetylation level. The top down LC-MS approach used here 
detects changes in histone expression ratios that are greater than ~10%, which 
translates to millions of nucleosomes experiencing histone remodeling (i.e., histone 
variant substitution or changes in modifications). 
Another possibility to explain the HDAC compensation effect observed here is 
that different HDACs have different non-histone substrate targets. It was shown that 
HDAC1 deacetylates p53 in vitro and in vivo and SIRT1 also binds to and 
deacetylates p53 [42, 43, 44, 45].  It is also possible that knockdown efficiency is not 
high enough to cause loss in HDAC function at sufficiently high levels to alter bulk 
histone acetylation. A small portion of HDAC protein left in the cells may still have 
sufficient activity to maintain global histone acetylation level. 
Inhibition of HDACs by broad spectrum inhibitors caused hyperacetylation on 
call core histone proteins. However, our data from class I selective reagents, valproic 
acid and apicidin, suggest that inhibition of certain HDACs is sufficient to induce 
global histone hyperacetylation at levels comparable to broad spectrum HDACi 
reagents. Clearly, biochemical HDAC inhibition assays performed in vitro do not 
reflect the actual inhibition occurring in live cells. It is possible that these two 
compounds do not have their purported HDAC selectivity in whole cells. Together 
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with the knockdown experiments, our data suggest that global human histone 
acetylation is regulated by multiple class I (and II) HDACs, not individual HDACs. 
Our LC-FTMS based histone profiling provides the sensitivity and resolution 
for a cell-based HDAC (or HAT) inhibitor screen. Based on the knockdown results, 
global histone acetylation levels may not detect single HDAC specific inhibitor 
screening. Rather, a kinetic assay [28] using cell lines with varying propensity for 
hyperacetylation could be used as a method to better screen for specific HDACi 
activity, which should yield lower acetylation levels vs. broad spectrum inhibitors.  
Further, the use of different cell lines with varying overall HDAC activity (as judged 
by bulk histone acetylation levels) could be compared to their metastatic potential in 
animal models with further study using our efficient platform. 
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Figure 2.1 LC-FTMS profile of core histones from HeLa S3 cells. (A) Total Ion 
Chromatogram (TIC) of core histones from ~10
7
 HeLa S3 cells. (B) Spectra of each 
core histone. Each isotopic distribution represents different modified forms or histone 
variants. 
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Figure 2.2 TIC and partial FT mass spectrum of histone H4 obtained from 10
6
 (A), 
10
5
 (B) and 5x10
4 
(C) 293T cells. 
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Figure 2.3 Deviation of different H2B variants from HeLa cells and 293T cells. (A) 
Spectrum of histone H2B from HeLa cells and 293T cells. (B) Relative percentage of 
different H2B variants from different samplings. 
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Figure 2.4 Highly accurate determination of mass for histone H4. 
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Figure 2.5 Knockdown of HDAC1 and HDAC2 does not affect global histone 
acetylation of 293T cells. (A) Western blotting showing knocking down of HDAC1, 
HDAC2 only or both in 293T cells. (B) Spectra of histone H4 from control cells and 
HDAC knock down cells. 
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Figure 2.6 Knock down of HDAC3 by shRNA does not affect global histone 
acetylation of HeLa S3 cells. (A) Western blotting showing knock down of HDAC3 
in HeLa S3 cells. (B) Spectra of histone H3.1, H3.2 and H4 from control cells and 
HDAC3 knock down cells. 
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Figure 2.7 Spectra of hyperacetylated core histones from sodium butyrate treated 
293T cells. 
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Figure 2.8 Spectra of hyperacetylated core histones from TSA treated 293T cells. 
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Figure 2.9 Inhibitors that show specificity during in vitro assays (AP and VPA) 
induce similar hyperacetylation as the broad spectrum inhibitor, TSA. 
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Figure 2.10 Spectra of histones from anacardic acid treated 293T cells. Decrease of 
acetylation level was observed on H2A and H2B. 
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Figure 2.11 Histone H4 from 293T cells has a higher acetylation level than that from 
HeLa cells. (A). Spectra of histone H4 from asynchronized HeLa cells and 293T cells. 
(B) Spectra of histone H4 from TSA treated HeLa cells and 293T cell. 
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Chapter 3. Quantitative proteomics revealed primary metabolic changes in 
oncogene induced senescent cells 
The information and contents of this chapter were largely adapted from this 
manuscript which will be submitted by defense date: Li, M.; Sweet, S.; Tipton, J. D.; 
Durbin, K. R.; Zheng, Y.; and Kelleher, N. L., Oncogene Induced Cellular 
Senescence Elicits an Anti-Warburg Effect. 
 
3.1 Introduction 
In normal tissues, the correct proliferative balance is carefully maintained by 
the highly regulated process of cell division. Cell cycle checkpoints are used by the 
cells to monitor and regulate the progress of the cell cycle. Checkpoints prevent cell 
cycle progression at specific points, allowing verification of necessary phase 
processes and repair of damaged DNA. The cell cannot proceed to the next phase 
until checkpoint requirements have been met. Cancers arise as somatic cells escape 
the controls which normally restrain them against unregulated expansion in renewable 
tissues [1]. Evolutionally, several mechanisms have developed to prevent 
uncontrolled cell division. These mechanisms work coordinately in an extraordinarily 
effective way to suppress tumorigenesis. Given the trillions of cells in a multicellular 
organism which are constantly exposed to cancer causing environmental insults, the 
development of cancer is relatively rare.  
Cellular senescence is one of the tumor-suppressing mechanisms [1]. It is 
characterized by the inability of cells to proliferate in the presence of abundant 
nutrients and mitogens. The senescence phenomenon was first associated with aging 
as Hayflick and colleagues observed that normal human fibroblasts lost their 
proliferative capacity after a finite number of cell divisions in culture [2]. Senescent 
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cells display a characteristic phenotype, including enlarged cell size, flat vacuolated 
cell morphology, inability to synthesize DNA, formation of senescence-associated 
heterochromatin foci (SAHF) and expression of a senescence-associated β-
galactosidase activity [3]. A similar phenotype can occur in “young” cells in response 
to multiple stimuli, including DNA damage, oncogenic signals and oxidative stress 
[4].   
Oncogene activation acting to potentiate or overstimulate normal growth 
signaling is a hallmark of cancer [4]. However, in “normal” cells oncogene activation 
does not lead to transformation, but instead provokes cellular senescence. Expression 
of a variety of oncogenes, including HRAS [5], BRAF [6], E2F1 [7] and MYC [8], 
drives a burst of cell hyperproliferation followed by a proliferation slow down and 
eventually cell growth arrest. It has recently been observed that oncogene induced 
senescence is associated with activation of the DNA damage response (DDR) [5, 9]. 
DNA damage signals contribute to activation of the p53 and pRB pathways, two key 
regulators of the senescence program, indicated by the fact that inactivation of either 
one usually abolishes cellular senescence in both mouse and human cells [10].  
Cellular senescence serves as a tumor-suppression process in two ways to 
inhibit proliferation. First, cell growth arrest certainly blocks tumor growth. Second, 
proliferation arrest should prevent the acquisition of additional mutations that can 
drive oncogenic events during DNA replication and mitosis. Even though cancer cells 
escape the senescence program, they still retain the capacity to undergo senescence 
[4]. From a potential therapeutic perspective, senescence initiated by genotoxic stress, 
which includes chemotherapeutic drugs, is able to contribute to tumor regression in 
vivo [11, 12]. In addition, senescent cells are able to secret immune regulators which 
can trigger clearance of senescent cells by the innate immune system [13]. Moreover, 
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cellular senescence could serve as a backup plan to inhibit tumor growth when tumors 
have defects in apoptotic pathways or developed resistance to chemotherapeutic drug-
induced apoptosis [3]. 
Though great progress with regard to understanding the senescence phenotype 
and underlying molecular mechanisms has been made over the last decade, a global 
view at the systems level is still lacking. It has been shown that senescent cells display 
a distinct gene expression profile at the transcriptome level [14], with such “omic” 
studies mostly focused on replicative senescence [15, 16]. Moreover, transcriptome 
dynamics do not reflect directly changes at the proteome level [17, 18]. Hence a 
mechanistic investigation of the proteome in oncogene induced senescent cells could 
provide information about differential regulation of responsive genes in the 
senescence program.  
We applied quantitative mass spectrometry to study protein expression 
changes in oncogene induced senescent (OIS) cells. SILAC allowed us to identify 
proteins and quantify their expression level changes in senescent cells. The sub-
proteome upregulated in senescent cells is in agreement with the fact that senescent 
cells were arrested in G1 phase of the cell cycle and cell growth could be uncoupled 
with cell division. Upregulation of proteins involved in oxidative phosphorylation and 
downregulation of proteins involved in glycolysis suggested an altered metabolism 
which is opposite of the Warburg effect in cancer cells. These findings revealed a 
metabolic signature of oncogene induced senescence and furthers our understanding 
of the senescence program and its antagonistic role to the development of cancer. 
 
3.2 Experimental procedures 
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Cell culture and gene transfer. Human diploid fibroblast cells IMR-90 were 
purchased from ATCC and cultured in DMEM supplemented with 10% FBS and 
antibiotics. DMEM-Galactose media was prepared with DMEM glucose free media 
(Invitrogen) and 10 mM galactose. The retroviral vectors (pBabe-Puro and pBabe-
Ras(H-RasV12)) were kind gifts from Dr. Scott Lowe at Cold Spring Harbor 
Laboratory. Retroviral scramble shRNA and PDK-1 shRNA were purchased from 
Origene Technologies. Retroviruses were packed using phoenix cells (ATCC) as 
described [19]. The pseudo-retrovirus used in SILAC experiments with VSV-g were 
packed and concentrated at the Vector Core facility at University of Michigan.  
SA-β-gal assays and SAHF images. SA-β-gal activity was detected as previously 
described [19]. DNA was visualized by DAPI (1 µg/mL) staining. 
SILAC labeling. “Heavy” media were prepared in house with L- 
13
C6, 
15
N4 –arginine, 
L-
13
C6, 
15
N2-lysine and dialyzed FBS. IMR-90 cells were cultured in heavy media for 
3 days prior to retroviral infection. Concentrated retroviruses containing pBabe-Puro 
plasmid were diluted with heavy media in a 1:20 ratio to reduce light amino acid 
incorporation during virus infection. The infected population was selected in heavy 
media with 2 µg/mL puromycin (Sigma) for 2 days and cultured in fresh heavy media 
for another 6 days. 
Protein harvest, fractionation and digestion. Control cells and senescent cells were 
trypsinized and counted by using a hemocytometer. Then the cell pellet was washed 
by cold PBS for 3 times and lysed in nuclear isolation buffer containing 15 mM Tris–
HCl; pH 7.5, 60 mM KCl, 11 mM CaCl2, 5 mM NaCl, 5 mM MgCl2, 250 mM sucrose, 
1 mM DTT, 10 mM sodium butyrate, protease inhibitor cocktails (Sigma), 
phosphatase inhibitor cocktails (Sigma) and 0.3% NP40. The cell lysate was 
centrifuged at 1000 × g for 5 min. at 4
o
C. The supernatant was saved as cytosolic 
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fraction. The pellet (nuclear fraction) was dissolved in 50 mM Tris buffer with 4% 
SDS supplemented with 10 mM sodium butyrate, 1 mM DTT, phosphotase inhibitor 
cocktails and protease inhibitor cocktails. Protein concentration was determined by 
BCA assay (Fisher). Equal amounts of the cytosolic or nuclear proteins from control 
and senescent cells were mixed respectively, resulting in 80-100 µg of total proteins.  
Protein mixtures were separated by 1D SDS-PAGE, using 1mm NuPage 
Noves Bis-Tris 4%-20% gradient gels (Invitrogen) according to the manufacture‟s 
instructions. The gel was stained with Coomassie Blue using mass spectrometry 
compatible staining kit (Thermo Fisher Scientific) and destained in HPLC H2O. Each 
gel lane was cut into 14 slices and protein bands were excised and digested with 
trypsin as described previously [20]. Digested peptides were extracted from the gel 
pieces and dried down in a speed-vac prior to storage at -80
o
C. 
NanocapillaryLC-MS/MS. Digested proteins were separated by online reverse-phase 
nanoscale capillary liquid chromatography (nanoLC) coupled with electrospray 
tandem mass spectrometry. The peptide mixtures were resuspended in 10 μL of buffer 
A (H2O containing 0.2% formic acid) and loaded to a trap column (150 µm i.d., in-
house packed with RP C18 10 µm resin) using an Eksigent 1D+ autosampler 
(Eksigent technologies, Dublin, CA) at a high flow rate at 5 µL/min. Subsequently, 
the peptides were eluted off the trap column and further separated by an analytical 
column (75 μm × 10 cm) with an integral fritted nanospray emitter (PicoFrit, New 
Objective, Inc., Woburn, MA) containing 5 μm C18 resin at a flow rate of 300 nL/min. 
A 120 min. gradient with buffer A (as above) and buffer B (5% H2O/95% acetonitrile, 
both containing 0.2% formic acid) was used: buffer B concentration increased from 
5% to 30% in 50 min. and from 30% to 45% in 20 min. Within the next 2 min., buffer 
B was ramped to 80% and remained at 80% for 5 min. before declining to 5% in 
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another 2 min. Then the column was further washed by 2 gradients from 5% B to 80% 
B in 10 min. and then equilibrated at 0% B up to 120 min. 
Samples were analyzed on a 12 Tesla LTQ-FT Ultra (Thermo Fisher Scientific, 
San Jose, CA) instrument fitted with a digitally controlled nanospray ionization 
source (PicoView DPV-550, New Objective, Inc.). The mass spectrometer was 
operated in data dependent mode to automatically switch between MS and MS/MS 
acquisition. Survey scan spectra were acquired in the FT-ICR cell from m/z 400 to 
1600 with resolution R=170,000 at m/z 400 and AGC setting at 1,000,000 ions. The 
MS/MS spectra were acquired in the linear ion trap. The five most intense ions were 
sequentially isolated and fragmented in the ion trap using CID with a target value of 
30,000 and max fill time of 150 milliseconds. Dynamic exclusion was set to 30 
seconds with 2 repeats. An activation Q=0.25 and activation time of 30 milliseconds 
was applied to MS/MS acquisitions.  
Data analysis. SILAC-MS data were analyzed by MaxQuant software (v 1. 0. 13. 13) 
[21]. Proteins were identified by database searching using Mascot (Matrix Science 
Ltd., Beachwood, OH) against the human IPI database supplemented with frequently 
observed contaminants and reverse sequence of each entry. Search parameters 
specified a MS deviation of 7 ppm and an MS/MS tolerance at 0.5 Da. Up to three 
miscleavages were allowed. Carbamidomethylation of cysteine was set as a fixed 
modification and oxidation of methionines and N-terminal protein acetylation were 
allowed as variable modifications. The false discovery rates (FDR) at the peptide and 
protein level were both set to 1% and proteins identified with one unique peptide were 
manually validated. All the post-search bioinformatics analysis was performed with 
the lead proteins. 
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Gene Ontology (GO) analysis. GO annotations of cellular component were retrieved 
from UniProt database. Counts of proteins for each selected cellular compartment 
were used to generate the pie chart. GO analysis of cellular processes was performed 
using FuncAssociate 2.0 [22] which uses a Monte Carlo simulation approach to 
determine the significance of grouped gene sets. We set the adjusted p value estimated 
from the results of 1000 simulated null hypothesis queries less than 0.001 as 
significant. 
Western blotting. Western blotting analysis was carried out using 20 µg of whole cell 
lysate. The membranes were probed with primary antibodies against p16 (1: 200, 
Santa Cruze), HDAC1 (1: 1000, Millipore), HDAC2 (1: 1000, Millipore), Cox IV (1: 
1000, Cell Signaling Technology), PDH (1: 1000, Cell Signaling Technology), PDH 
E1-α subunit [phospho Ser293] (1: 1000, Novus Biologicals), PDK-1 (1: 1000, Cell 
Signaling Technology), and α-tubulin (1: 1000, Cell Signaling Technology) in 0.05% 
Tween 20/PBS and then with an HRP-labeled secondary antibody (1:5000; Santa 
Cruz). Proteins were visualized by chemiluminescence with ECL Western blotting 
detection reagents (Pierce). 
 
3.3 Results 
3.3.1 Quantitative analysis of protein expression changes in senescent cells 
To characterize protein expression level changes in oncogene induced 
senescent cells, IMR-90 cells were SILAC-labeled and transduced with pBabe-puro 
plasmids (control) and its proteome was compared to that of oncogenic Ras induced 
senescent cells, 6 days after puromycin selection. Several well established senescence 
markers were used to confirm that those cells indeed underwent oncogene induced 
senescence, including SAHF formation, β-Gal staining and upregulation of protein 
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p16 (Figure 3.1).  As primary fibroblast cells have a slower growth rate relative to 
other cancer cell lines, the standard protocol was adapted to get sufficient time for a 
full labelling of all proteins with heavy isotope version of the amino acids (Figure 3.2). 
Proteins from an aliquot of labeled cells were digested and analyzed by nano-
LCMS/MS and a labelling efficiency greater than 98% was observed. We also 
observed no Arg-Pro conversion in these labeled cells [23]. Since senescent cells 
displayed a dramatic cell size enlargement, especially the cytoplasm, we measured the 
protein content from the cell nucleus and cytoplasm. The enlarged cytoplasm did 
translate into a ~4 fold increase in amount of proteins in the cell cytoplasm (Figure 
3.3). Hence, the same protein amounts were mixed during sample preparation instead 
of mixing the same number of cells in the SILAC experiments. We used high 
resolution MS to identify 2206 proteins from 3 biological replicates at 1% FDR. As 
shown by the Venn diagram in Fig. 3.4a, a list of proteins was identified for each of 
the three biological replicates, with a large portion of proteins identified in at least 
two biological replicates. Here, we conservatively considered protein abundance 
difference greater than 2 fold as significant changes. More than 80% of all the 
identified proteins were of constant abundance within a factor less than 2 (Figure 
3.4b). The identified proteins were subdivided into different categories based on their 
subcellular localization (Figure 3.4c). Figure 3.5 lists the protein ratios of selected 
proteins from nuclear and cytosolic fractions quantified from at least two biological 
replicates, revealing good reproducibility of the replicated sampling. 
 
3.3.2 Proteins upregulated in oncogene induced senescent cells 
In our data set, 179 proteins showed significant increase of protein expression 
levels which is ~ 10% of the identified proteome. In this list, several proteins have 
already been shown to play a role in cellular senescence from previous literatures. 
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Fibronectin is one of the proteins shown to be upregulated in replicative senescent 
cells both at mRNA and protein level [24]. Nucleophosmin has been shown to be able 
to induce senescence in murine primary fibroblast cells by overexpression [25]. Also, 
some protein components of SAHFs, including HP1γ [14] and prohibitin [26] showed 
increased protein expression level in our data set. 
In order to visualize the internal linkages of these upregulated proteins on a 
systems level, we applied the network analysis tool „STRING‟ [27] which maps all 
the upregulated proteins form our data set onto the known set of functional protein-
protein interactions.. We fetched all interactions based on a metric, "confidence score", 
defined by STRING to represent interaction confidence, that had a confidence score 
0.7 (i.e., high confidence). In the complex protein-protein interaction network, some 
proteins were grouped into several clusters (Figure 3.6a). The first cluster includes a 
large number of heterogeneous nuclear ribonucleoproteins (hnRNPs) and RNA 
splicing factors which function during transcription and mRNA processing. The 
second cluster includes eukaryotic translation initiation factors and ribosomal proteins. 
The other two clusters have proteins involved in oxidative phosphorylation and ATP 
synthesis. In contrast, we randomly selected sets of ~200 proteins as null hypotheses 
and did not observe such noticeable aggregates of functional modules with the same 
analysis (Figure 3.6b).  
 
3.3.3 Protein synthesis is required for OIS 
To study the function of the increased expression level of a group of 
functionally connected proteins in senescent cells, we examined the involvement of 
protein synthesis in senescence program. Senescent cells were treated with protein 
synthesis inhibitor, cycloheximide, at a final concentration of 1µg/mL for 2 days after 
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overexpression of oncogenic Ras and incubated in fresh media for another 4 days. As 
shown in Figure 3.7, treatment with cycloheximide abolished the senescence 
phenotype indicated by negative SA-β-Gal staining. This suggests that functional 
protein synthesis is required for developing the senescence phenotype. 
 
3.3.4 Proteins downregulated in OIS cells 
Compared to upregulated proteins, a smaller number of proteins showed 
decreased protein expression level in senescent cells. 37 proteins, nearly 2.5% of the 
identified proteome, showed significantly decreased protein abundance in senescent 
cells. The list of downregulated proteins was submitted to the FuncAssociate server 
[22] to search for the over-represented attributes of GO terms. GO terms with p_adj 
≤0.01 were sorted by increasing p_adj values – based on, for a given GO term, the 
number of observed associated proteins in the list of N, compared with the number of 
expected associated proteins in a random list of N human proteins. The GO term 
description with the lowest p_adj value (≤0.001) was Glycolysis (Figure 3.8A). 
Randomly selected proteins did not show such enrichment suggested by higher p_adj 
(Figure 3.8B). Proteins in the glycolysis category include Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), Enolase (ENO2, ENO3) (Figure 3.5), 
Phosphoglycerate kinase 1 (PGK), and Phosphofructokinase (PFKP). Along with the 
glycolytic enzymes, we also observed decrease expression of glucose transporter 
GLUT1. From previous studies, inhibition of glycolytic enzymes has been shown to 
be able to induce senescence and overexpression of some of the glycolytic enzymes 
can bypass replicative and ras induced senescence [28]. 
 
3.3.5 Global proteome changes indicate an altered metabolism in senescent cells 
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The observation that decreased abundance of proteins involved in glycolysis 
and increased protein expression level on oxidative phosphorylation in senescent cells 
is opposite as the Warburg effect, known as aerobic glycolysis increases in most 
cancer cells regardless of the accessibility of oxygen [29]. 
Glycolysis is a universal metabolic pathway that converts glucose to pyruvate 
and release free energy to produce ATP. In most mammalian cells, glucose is 
metabolized to carbon dioxide by oxidation of pyruvate in the tricarboxylic acid (TCA) 
cycle and following oxidative phosphorylation in the presence of oxygen. On the 
other hand, glycolic pyruvate is converted to lactic acid in the absence of oxygen. In 
senescent cells, because of decreased expression of glycolysis proteins, the production 
of pyruvate should be decreased. However, with increased oxidative phosphorylation 
proteins, it suggests that the pyruvate flux to the TCA cycle and oxidative 
phosphorylation must increase. Pyruvate dehydrogenase (PDH) catalyses the first step 
in this process, namely the conversion of pyruvate to acetyl-CoA in mitochondia. The 
activity of PDH is controlled by phosphorylation. When non-phosporylated, PDH is 
active, whereas the phosphorylated form is inactive and resulting the channeling of 
pyruvate to lactate. Therefore, we examined the activity of PDH in senescent cells as 
reported by its phosphorylation status. In senescent cells, the expression level of PDH 
is slightly increased while the phosphorylated form is significantly decreased (Figure 
3.9). This data are consistent with PDH being more active in senescent cells, causing 
more pyruvate flow to oxidative phosphorylation. This decreased phosphorylation of 
PDH was likely because one of the PDH kinases, e.g., PDK-1‟s expression level 
decreased in senescent cells. This was directly tested by Western blotting (Figure 3.9). 
Meanwhile, one of the proteins of oxidative phosphorylation, COX IV, showed 
elevated protein abundance, further confirming the MS data. Together these data 
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suggested that oncogene induced senescent cells, while not dividing but growing, 
shifted their metabolism preferably to oxidative phosphorylation to maximize ATP 
synthesis and biomass production. 
 
3.3.6 Altered metabolism can trigger senescence phenotype 
 To evaluate the contribution of altered metabolism to cellular senescence, we 
cultured cells in DMEM/Galatose media to restrict glycolysis as a mimic of 
downregulation of glycolic proteins as well as knocking down PDK-1 to increase 
pyruvate influx to oxidative phosphorylation. Either one of these two treatments 
slightly increased senescent cell population in culture; while the combination of these 
two significantly increased senescent cell population (Figure 3.10). This suggested 
that altered primary metabolism was not only a part of senescence phenotype but also 
a contributor of the cellular senescence program. 
 
3.4 Discussion 
 
Previous functional proteomic studies have identified some proteins 
differentially regulated in replicative senescence from different organisms [30, 31, 32]. 
Due to a much smaller data set and fewer proteins identified from their studies, they 
mainly focused on the different expression levels of single proteins. Our study has 
been the first functional proteomic analysis of oncogene induced senescence and 
provided biological information at the system biology level which could improve our 
understanding of cellular senescence and cancer. 
If the protein abundance correlated directly with the activity of the biological 
processes they were involved in, upregulation of the hnRNPs and RNA splicing 
factors might indicate a higher transcription rate and RNA processing activity. 
hnRNPs have been shown to be involved in a wide variety of cellular processes in the 
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nucleus, including alternative pre-mRNA splicing, transcriptional regulation, 
maintenance of telomere length and immunoglobulin class-switch recombination, as 
well as regulation of mRNA in the cytoplasm [33]. Abundance increase of eukaryotic 
translation initiation factors and ribosomal proteins could fulfil the requirement of 
augmented protein synthesis. With the enlarged cytoplasmic morphology, more 
proteins might be needed to sustain the cell structures and other associated biological 
activities. Also, increased protein synthesis can support the production of extracellular 
matrix protein, such as fibronectin, and the characteristic senescence associated 
secretome [34]. To do so, much more energy might be needed which explains the 
elevated abundance of proteins for ATP synthesis. This contrasts with the recent 
reports that down-regulation of ATP synthase expression has been found in breast and 
gastric adenocarcinomas, as well as in kidney, liver, squamous oesophageal, colon 
and lung carcinomas [35, 36, 37]. With all above, it suggested that though senescent 
cells stopped dividing they kept biological activities operating at even higher levels 
than control cells.  
Oncogene induced cellular senescence has been characterized as an 
irreversible cell cycle arrest at G1 phase of the cell cycle [19]. G1 phase is the major 
period of cell growth in the cell cycle and when new cellular organelles are being 
synthesized, the cell requires both structural proteins and enzymes, resulting in a great 
amount of protein synthesis and a high metabolic rate in the cell. Our quantitative 
proteomic data showing that proteins involved in transcription, translation and ATP 
synthesis were upregulated in oncogene induced senescent cells confirmed that these 
cells shared common features with cells in the G1 phase at the entire proteome level. 
This also supports the notion that cell growth could be uncoupled with cell division. 
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It has been demonstrated that in primary cells, increased Ras expression 
results in an increased level of intracellular reactive oxygen species (ROS) [38]. This 
ROS increase appears to be important for inducing and maintaining cellular 
senescence because either treating the cells with hydrogen peroxide scavenging agents 
or culturing Ras expressing cells in low oxygen blocked Ras-induced senescence [38]. 
Oxidative phosphorylation is an essential part of metabolism to transfer electrons 
from electron donors to electron acceptors to release energy. During this process, it 
produces reactive oxygen species such as hydrogen peroxide and superoxide, which 
lead to propagation of free radicals, damaging cells. With an upregulation of proteins 
involved in oxidative phosphorylation, it suggested a possible explanation for the 
increased ROS level in oncogene induced senescent cells. However, how oncogene 
expression caused upregulation of oxidative phosphorylation proteins and the link 
between OIS and ROS remained to be elucidated in the future. 
A very common characteristic of tumor cells is that the tumor cells exhibit 
increased glycolytic metabolism compared with normal cells and this abnormal 
glycolytic metabolism has been discussed as a potential seventh hallmark of cancer 
(39) beyond the six widely accepted hallmarks of cancer (40). Our results of protein 
expression pattern in senescent cells suggested alterations in cellular metabolism 
which is opposite of that observed in cancer cells (Figure 3.11). In senescent cells, 
protein expression level, as well as protein activity changes at a set of proteins 
involved in metabolism, cause a different metabolic profile which decreases 
glycolysis rate and channels more pyruvate to oxidative phosphorylation as the 
opposite of that in cancer cells. We may also add the altered metabolism favoring 
oxidative phosphorylation over aerobic glycolysis as a part of the oncogene induced 
senescence program. Manipulated cell metabolism mimicking the profile is able to 
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trigger senescence phenotype. It implies the importance of cocktail therapy by 
targeting multiple targets to cause a systematic impact on cell growth. By further 
studying the underlying mechanism controlling the molecular switch of the metabolic 
profiles it could be of great importance to investigate if cancers have to and how they 
disrupt the metabolism control and hence bypass senescence. Restoration of the innate 
program in cancer cells could be beneficial for cancer therapy. 
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Figure 3.1 Selected senescence markers. (A) SAHF formations; (B) β- Gal staining; 
(C) Upregulation of P16INK4A. 
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Figure 3.2 Experimental design of SILAC 
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Figure 3.3 Increase of total cytosolic proteins in senescent cells 
 
 
 
 
 
 
 
 
  69 
 
Figure 3.4 Identified proteome from SILAC. (A) Number of proteins identified form 
three biological replicates; (B) Fold change distribution of the identified proteome; (C) 
Subsellular distribution of the identified proteome. 
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Figure 3.5 Selected protein expression level changes in senescent cells 
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Figure 3.6 STRING analysis of identified proteome. (A) STRING analysis of 
upregulated proteins displayed clustered functional modules in protein-protein 
interaction networks; (B) Randomly picked proteins showed no aggregation of 
protein-protein interaction modules. 
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Figure 3.7 Protein synthesis inhibition abolished senescence program. 
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Figure 3.8 Gene ontology analysis of downregulated proteins in senescent cells. (A) 
Downregulated proteins are highly enriched in glycolysis. (B) Randomly picked 
proteins do not show any significant enrichment. 
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Figure 3.9 Western blot analysis of proteins involved in cell metabolism. 
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Figure 3.10  (A) Knock down of PDK-1 shown by western blotting analysis. (B) SA-β 
Gal staining of cells treated with shRNA and modified cell media. (C) Quantitation of 
positive SA-β Gal staining cells from B. 
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Figure 3.11 Model of altered metabolism in oncogene induced senescence (left) 
compared to normally replicating cells (middle) or cancerous cells (right). 
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Chapter 4. Histone modifications in senescent cells characterize a global 
formation of heterochromatin 
Dr. Steve Sweet, Dr. Jeremiah Tipton, Kenneth Durbin, and Dr. Yupeng Zheng 
helped with the histone methylation characterization by SRM. 
  
4.1 Introduction 
The eukaryotic DNA is highly organized into compact structures. The major 
morphologically distinct form of chromatin – heterochromatin – is more compacted 
and generally transcriptionally inactive, while the minor class – euchromatin – is less 
condensed and generally more transcriptionally active. Heterochromatin was 
originally defined as the set of chromatins that stain intensely at prophase and 
maintain a compact organization throughout the cell cycle. Large chromosomal 
portions, or even entire chromosomes, are made up of heterochromatin in a wide 
diversity of eukaryotes [1]. The fundamental structural basis for the different degrees 
of compaction and hence for different potential transcriptional activity have been 
proposed to depend on how nucleosomes are stacked in a chromatin fibre [2]. 
Heterochromatin can be further classified into two groups, including facultative 
heterochromatin and constitutive heterochromatin. Facultative heterochromatin 
regions are subject to control in that they can be alternatively silenced or functional 
during different stages of development. In contrast, constitutive heterochromatin, 
usually found near centromeres and telomeres, consists mostly of repetitive DNA 
sequences [1]. 
Histone modifications and their combinatorial patterns have a huge potential 
in storing epigenetic information and regulating genetic functions. Particularly, 
histone methylation, perhaps more than any other modification, has demonstrated the 
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power of controlling over DNA-based functions, regulating fundamental biological 
processes including gene transcription and DNA repair [3]. For example, methylation 
of histone H3 at lysine 9 (H3K9me) is characteristic in HP1-associated 
heterochromatin repression. PcG-mediated gene repression is characterized by 
H3K27me and seems to primarily control genes involved in developmental decisions. 
Heterochromatin has been proved to be associated with some specific histone 
modifications. The development of antibodies specific for acetylated histones allowed 
visualization of the levels of acetylation in different regions of chromatin. These 
studies showed that pericentromeric heterochromatin was relatively underacetylated 
compared to euchromatin [4]. Underacetylation of histones H3 and H4 was also 
observed for the heterochromatin of the inactive X chromosome in mammals, which 
forms the condensed Barr body [5]. Determining the relationship between histone 
methylation and heterochromatin first came from the discovery of a histone 
methyltransferase Su(Var)39 specific for histone H3K9. Targeted inactivation of this 
gene in mice causes disruption of centromere functions [6]. Using highly specific 
methyl-lysine antibodies, together with quantitative mass spectrometry, researchers 
provided evidence for the selective presence of H3-K9 trimethylation and H3-K27 
monomethylation at pericentric heterochromatin [7]. In contrast, the form of 
facultative chromatin found on the inactive mammalian X chromosome is 
characterized by the presence of histone H3K27 trimethylation [8]. 
Histones may get methylated on either arginine (R) or lysine (K) residues. 
Arginine side chains are subjected to mono- or di-methylation, either symmetrically 
or asymmetrically, whereas the lysine side chains may be mono-, di- or tri-methylated. 
Since a methyl group is relatively small and its addition does not neutralize the 
charges of either lysine or arginine residues, it is unlikely that methylation alone will 
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significantly change local chromatin structures [3]. It is more likely that it creates 
binding sites for chromatin associated proteins that contain specialized binding 
domains which could „read‟ different methylation markers. One of the well 
demonstrated examples is the interaction between HP1 and histone H3K9 
trimethylation. So far, there are more than 20 known sites of methylation on histones. 
If we take into consideration all possible methylations of lysine and arginine residues, 
there are potentially 3×10
11
 distinctive methylation states of histone proteins.  
Similar to histone acetylation, the histone methylation state is balanced by 
histone methyltransferases (HMTs) and histone demethylases. There are three classes 
of histone methyltransferases: SET domain containing lysine methyltransferases, non-
SET domain lysine methyltransferases, and arginine methyltransferases [9]. All of 
them use S-adenosylmethionine (SAM) as a coenzyme to transfer methyl groups to 
histones. The discovery of the first histone methyltransferase proposed the potential 
for the methylation 'mark' to control epigenetic events and the recent discovery that 
methylation can be reversed by demethylases has changed the dogma that histone 
methylation is a 'permanent' mark. 
The SET domain was discovered as a revolutionarily conserved 120–150 
amino acid sequence present in several Drosophila genes that are involved in 
chromatin-mediated gene regulation during development, including Su(var)3-9, 
Enhancer of Zeste(E(Z)), and Trithorax(trx) [10]. Four SET domain sub-families have 
been identified, the SUV39 family, the SET1 family, the SET2 family, and RIZ 
family, based on similarities between human SET domains and yeast SET domains. 
The SUV39 protein was the first histone methyltransferase to be identified and it 
catalyzes the methylation of K9 in H3. Human SUV39h1/h2 methyltransferases 
associate with the Rb tumor suppressor. The interaction between Rb and Suv39H1 
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leads to H3 K9 methylation at the promoters of Rb target genes such as E2F, and is 
associated with their repression in senescent cells [11]. Loss of SUV39h1/h2 function 
impairs heterochromatin and genome stability, which might contribute to tumor 
formation [6]. 
 Traditionally, histone modifications have been discovered and monitored by 
using site-specific antibodies or 
32
P-labeling followed by Edman degradation. Mass 
spectrometry (MS) has complemented the biological approaches, characterizing the 
myriad of histone modifications. A variety of MS methods have been developed to 
quickly profile [12] and fully characterize histone modifications [13, 14, 15, 16, 17, 
18, 19, 20]. However, because of the complexity of combinatorial modifications on 
histone H3, characterization and quantitation of each modification remains a 
challenge. Due to the presence of highly abundant basic residues on histone H3, the 
standard trypsin digestion generates small, irreproducible peptides that are often 
difficult to analyze by MS. Besides, the modifications on lysine residue would 
interfere with trypsin digestion which causes unreliable quantitation. Use of a 
propionylation reagent through chemical modification of lysine residues generates 
uniform tryptic-like peptides which are easily retained on RPLC columns and 
analyzed by MS. The development of a selected reaction monitoring (SRM) assay 
with triple quadrupole MS provided a useful tool to quantify isobaric modified 
peptides. This allowed us to quantitatively measure the methylation level changes in 
senescent cells. The methylation pattern changes on global chromatin suggested that 
the senescent cell might have a more compact heterochromatin structure.  
  
4.2 Experimental procedures 
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Cell culture and gene transfer. The cells were cultured and manipulated as described 
in chapter 3.  
Intact histone profiling. Intact histone proteins were purified and analyzed by LCMS 
as described in chapter 2. 
Chemical derivatization of histones. Histone proteins were purified from control and 
senescent cells as described in chapter 2 and dissolved in HPLC water at a 
concentration of 1µg/µL. 5 µg of histone sample was mixed with 5µL of 100mM 
ammonium bicarbonate buffer (pH 8.0). 1 µL of concentrated ammonium hydroxide 
was added to the sample. The sample was then mixed with 20µL of propionylation 
regent which consisted of 25% propionic anhydride and 75% methanol. The pH of 
sample was adjusted to 8.0 by adding ammonium hydroxide and the reaction was 
incubated at 37
o
C for 20 min. The derivatized histone proteins were dried down to 
approximately 5 µL and diluted with 50 µL 100mM ammonium bicarbonate and then 
digested with 0.25µg trypsin at 37
o
C overnight. The sample was then dried down and 
the same derivatiztion procedure was repeated to derivatize the N-terminal of the 
tryptic peptides. Finally, the peptides were dried down completely. 
NanocapillaryLC-LTQ-FTMS/MS. All digested peptides were separated by online 
reverse-phase nanoscale capillary liquid chromatography (nanoLC) coupled with 
eletrospray tandem MS. The peptide mixtures were resuspended in 10 μL of buffer A 
(H2O containing 0.2% formic acid) and loaded to a trap column (150 µm i.d., in-
house packed with RP C18 10µm resin) using an Eksigent 1D+ autosampler (Eksigent 
technologies, Dublin, CA) at a high flow rate of 5µL/min. Subsequently the peptides 
were eluted off the trap column and further separated by an analytical column (75 μm 
× 10 cm) with an integral fritted nanospray emitter (PicoFrit, New Objective, Inc., 
Woburn, MA) containing 5 μm C18 resin at a flow rate at 300 nL/min. A 60 min 
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gradient with buffer A (as above) and buffer B (5% H2O/95% acetonitrile, both 
containing 0.2% formic acid) was used: buffer B concentration increased from 5% to 
30% in 30 min. and from 30% to 45% in 10 min. Within the next 2 min., buffer B was 
ramped to 80% and remained at 80% for 5 min. before declining to 0% in another 2 
min. Then the column was equilibrated at 0% B up to 60 min. 
Samples were analyzed on a 7 T LTQ-FT (Thermo Fisher Scientific, San Jose, 
CA) instrument fitted with a digitally controlled nanospray ionization source 
(PicoView DPV-550, New Objective, Inc.). The mass spectrometer was operated in 
data dependent mode to automatically switch between MS and MS/MS acquisition. 
Survey scan spectra were acquired in the FT-ICR cell from m/z 400 to 1600 with 
resolution R=100,000 at m/z 400 and AGC setting at 1,000,000 ions. The MS/MS 
spectra were acquired in either the linear ion trap or the FTICR cell. The five most 
intense ions were sequentially isolated and fragmented in the ion trap using CID with 
a target value of 30,000 and max fill time of 150 milliseconds. Dynamic exclusion 
was set to 30 seconds with 2 repeats. An activation Q=0.25 and activation time of 30 
milliseconds was applied to MS/MS acquisitions. 
NanocapillaryLC triple quadrupole mass spectrometry. The derivatized peptides 
were resuspended in 20 µL H2O with 1% TFA. The nanoLC-MS system for peptide 
analysis consisted of a Dionex UltiMate 3000 coupled to a ThermoFisher Scientific 
TSQ Quantum QQQ mass spectrometer. Peptides were loaded onto a C18 trapping 
column (2 cm × 150 µm; Vydac 218MS C18-5µm) for five minutes at a flow-rate of 5 
µL/min in 0.1% TFA loading buffer. Peptides were separated by a gradient from 2 to 
35% acetonitrile over 26 minutes, in the presence of 0.1% FA. The analytical column 
(10 cm × 75 µm) consisted of the same C18 material as the trapping column; both 
were packed in-house. The QQQ settings were as follows: collision gas pressure of 
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1.5 mTorr; Q1 peak width of 0.7 (FWHM); cycle time of 3.5 s; skimmer offset of 10 
V; electrospray voltage of 2.6 kV. Nanospray was from a New Objective emitter with 
10 µm tip (FS360-20-10-N-20-C12), attached to a custom-built stage. SRMs were 
developed and data analyzed using Skyline software (v0.7; MacCoss Lab, University 
of Washington) [21]. Briefly, method development consisted of surveying a wide 
range of predicted b and y ions for each peptide; where isobaric forms of the peptide 
existed (e.g. K27 and K36 methylation forms of the H3 27-40aa peptide), transitions 
were selected that distinguished between the different forms. The most intense of 
these fragment ions (from 3 to 5 ions per peptide) were selected for collision energy 
optimization. Synthetic methylated histone peptides (Anaspec) were employed in 
SRM development. Peptides covered all K4 methylation states, all K9 methylation 
states, K9 and K14 acetylation, all K27 methylation states, all K36 methylations states; 
with the exception of the doubly acetylated K9K14 peptide, each peptide was only 
modified at a single position. The synthetic peptides spanned from H3 (1-21) and 
from H3 (21-44). They were propionylated and trypsin digested prior to use. The 
complete list of optimized SRM transitions is shown in table 4.1. 
Data analysis. Data generated by LTQ-FTMS/MS were searched against an in-house 
built database contains all human histone entries from UniProt database using 
Proteome Discoverer software for MS2 spectra acquired in ion trap and using 
ProSight software [22] for MS2 spectra acquitted in FTICR. Search parameters 
specified a MS deviation of 10 ppm and an MS/MS tolerance at 0.5 Da for 
fragmentation scans acquired in the ion trap or 10 ppm for fragmentation scans 
acquired by FTMS. Miscleavage was set to up to three. Propionylation (+56.026 Da) 
on the N-terminus of the peptides was set as a fixed modification, while oxidation of 
methionine (+15.995 Da) and N-terminal protein acetylation were set as a variable 
  84 
modification for all searches. For histone PTM searches, propionylation (+56.026 Da), 
acetylation (+42.010 Da), mono- (+70.042 Da), di- (+28.031 Da) and trimethylation 
(+42.046 Da) of lysine residues were selected as variable modifications. Histone 
monomethylation was searched as the sum of the masses for propionylation (+56.026 
Da) and methylation (+14.016 Da) because monomethylated residues can still be 
propionylated. Relative occupancy of each modification on a peptide was calculated 
by the following formula: (Peak area of a particular modified peptide)/(Sum of peak 
area of all modification status on the peptide). 
Data generated from triple quadrupole MS were processed using Skyline 
software [21], with Savitzky-Golay smoothing of peaks. Automatic peak assignment 
and retention times were checked manually. Total area was employed for downstream 
analysis. 
Western blotting. Western blotting analysis was carried out using 20 µg of whole cell 
lysate. The membranes were probed with primary antibodies against HDAC1 (1: 1000, 
Millipore), or HDAC2 (1: 1000, Millipore) in 0.05% Tween 20/PBS and then with an 
HRP-labeled secondary antibody (1:5000; Santa Cruz). Proteins were visualized by 
chemiluminescence with ECL Western blotting detection reagents (Pierce). 
 
4.3 Results 
4.3.1 Reduction of global histone acetylation accompanying senescence 
In order to examine the global histone modifications, we first analyzed the 
intact histones from oncogenic Ras induced senescent cells (6 days after puromycin 
selection) by reverse phase LC-MS (Figure 4.1). We observed a significant decrease 
of global histone acetylation levels from all core histone proteins in senescent cells. 
Histone H2A, H2B and H4 showed decreased intensity on their acetylated forms in 
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the spectra. Though H3 has a more complicated spectrum making it difficult to 
distinguish peaks amongst the modified forms, clear mass shift was still observed 
from higher m/z to lower m/z indicating deacetylation (Figure 4.2).  
To localize and quantify the modifications on specific lysine residues, we 
chemically derivatized bulk histones and digested them with trypsin to generate 
peptides that are easier to be retained on the HPLC column and analyzed by MS. 
Similarly, a peptide from histone H4 tail which has 4 potential acetylation sites also 
showed decreased acetylation level in senescent cells (Figure 4.3) but not methylation 
on the H4K20, which is the major methylation site on histone H4 [23]. Next, we 
examined the protein expression level of selected HDACs in senescent cells by 
Western Blotting analysis. No upregulation of HDAC1 or HDAC2 expression was 
observed in senescent cells (Figure 4.4) suggesting that global hypoacetylation in 
senescent cells may not result from changing a single HDAC‟s expression level. This 
was also in agreement with our earlier reports showing that knocking down one or 
two HDACs did not change global histone acetylation levels [12]. 
 
4.3.2 Discovery of a novel acetylation on histone H2A which decreased in OIS 
cells 
 One peptide corresponding to the sequence of histone H2A residues 12-17 was 
identified with an acetylation on the Lys-15 position by measuring the precursor mass 
in FTICR and fragment ion masses in ion trap. The same sample was then analyzed 
by applying high resolution MS/MS since high resolution MS/MS can increase the 
confidence in both identification and characterization of peptides [24]. The peptide 
mass was detected with a mass error less than 5 ppm (Figure 4.5A). 7 out of the most 
abundant 10 fragmentation peaks were successfully assigned to peptide fragments 
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with mass tolerance of 10 ppm (Figure 4.5B) thereby unambiguously localizing 
acetylation on Lys-15. This acetylation has never been reported in any previous 
literatures. The relative occupancy of this acetylation decreased from 45% to 20% in 
senescent cells (Figure 4.5C). 
 
4.3.3 Methylation pattern changes on histone H3 in OIS cells 
 Quantifying histone modification occupancy by measuring relative MS1 
intensities (Extracted ion chromatogram, XIC) has been successfully applied to 
different studies to reveal biological histone modification pattern changes [25, 26]. 
However, this methodology is not able to distinguish isobaric forms of multiple 
modifications on the same peptide. For example, histone H3 peptide 27-40 with 3 
methyl groups co-elutes off the column and may appear to be a mixture of peptides 
consisting K27Me3, K27Me2/K36Me, K27Me/K36Me2 and K36Me3. The usage of 
SRM has overcome this problem by measuring and comparing the intensities of 
fragment ions which are easily distinguishable by selecting transitions that are unique 
for each modification site.    
 By using this strategy, we have quantitatively analyzed methylation level 
changes in senescent cells on 4 different lysine residues (K9, K27, K36 and K79) on 
histone H3. It was observed that di- and tri-methylation on K27 significantly 
increased in senescent cells. In contrast, the methylation pattern on K36 shifted from 
di- and tri-methylation to mono-methylation in senescent cells (Figure 4.6). 
Methylation level on histone H3K79 slightly increased (Figure 4.7A). While histone 
H3K9 tri-methylation had been shown to be enriched on SAHFs, the methylation 
pattern on the global chromatin did not change significantly in senescent cells as di- 
and tri-methylation level remained at a low level (Figure 4.7B). 
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4.4 Discussion 
Our combined mass spectrometric analysis of histone modifications provided 
a comprehensive view of histone modification pattern in oncogene induced senescent 
cells. Histone acetylation, particularly at the promoter regions, is associated with 
transcription activation. It changes the local structures of chromatin and facilitates 
transcription associated proteins to get access to the chromatin. In our studies, we 
observed global hypoacetylation on all core histone proteins in oncogene induced 
senescent cells. However, at the proteome level, proteins involved in transcription, 
translation and energy production increased their expression level. This might indicate 
that global modification on histone proteins is not directly associated with 
transcription activity. Histone acetylation is controlled by the balance between histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). Due to the activity 
redundancy and compensation between different family members of the HAT and 
HDAC, the global histone acetylation might not be controlled by one or a few HATs 
or HDACs [12]. Disturbance of chromatin modifications by either HDAC inhibitors 
or downregulation of HAT could induce a senescence phenotype [27, 28]. This 
suggests a possible link between the global histone acetylation and the senescence 
phenotype.  
The completion of the human genome project and the advent of sequencing 
technology have led to a growing number of genome-wide studies of covalent 
chromatin modifications. H3K9me2 and H3K9me3 marks, in a region of 10 kb 
upstream and downstream of the transcription start site, have been reported to be 
mostly, but not uniformly, associated with gene silencing [29]. And these marks are 
important molecular signatures of SAHFs. SAHFs have been identified as a distinct 
type of facultative heterochromatin instead of constitutive heterochromatin 
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accumulated in senescent cells and responsible for silencing E2F target genes [30]. 
SAHFs contain several universal markers of heterochromatin, including histone 
hypoacetylation, methylation of lysine 9 of histone H3 (H3K9Me) and bound 
Heterochromatin Protein 1 (HP1) proteins [31]. However, markers of condensed 
chromatin in mitotic and apoptotic cells do not exist in SAHFs, such as phosphoserine 
10 or 28 of histone H3 (H3S10P, H3S28P) and phosphoserine 14 of H2B [32, 33]. 
SAHFs are also characterized by their depletion of linker histone H1 and enrichment 
in two other proteins, the histone variant macroH2A and HMGA proteins [32, 34]. 
Our observation that histone proteins are hypoacetylated in senescent cells was 
consistent with SAHF formation. However, the level of methylation on H3K9 did not 
change significantly in senescent cells at the global level. 
We have observed increase of di- and tri-methylation on H3K27 and decrease 
of di- and tri- methylation on H3K36. Previous studies have suggested that 
methylation of H3K27 correlated with gene repression [35, 36] and H3K36Me3 
associated with actively transcribed regions [35, 37]. Because proteins upregulated in 
senescent cells suggested a higher transcription and translation activity, the histone 
modifications pattern at the actively transcribed gene loci might have more 
acetylation and methylation on K36, as well as less methylation on K27. However, the 
global histone modification pattern is the opposite. Both hypoacetylation and 
methylation on K27 are features of heterochromatin. Other than these reported histone 
modifications enrichment at local foci, our data indicated a global change at the 
histone modification pattern. Unlike local histone modifications, revealed by 
techniques such as CHIP and fluorescence microscopy, reflects chromatin status at 
specific region of chromosomes, for instance, promoters, centromeres and telomeres, 
global histone modifications might reflect the chromatin structure at a higher level. 
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Considering the evidence that single chromosomes condense into a single SAHF [34], 
it is possible that the deacetylation and increase of methylation on K27 might occur 
throughout the entire genome and result in chromosome condensation and a more 
packed chromatin structure as a stress response.   
With more information from the genome wide approaches in the future, it will 
become clearer how much local chromatin modifications and global chromatin 
structures contribute to the maintenance of senescence state and how the chromatin 
modifiers function in cellular senescence. 
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Table 4.1 Summary of SRM transitions for histone H3 peptides 
Precursor 
M/Z Product M/Z 
Fragment 
ion CE Modified Sequence Peptide Note 
710.377548 186.076084 b1 40 E[+56]IAQDFK[+28]TDLR K79me2 
710.377548 288.203016 y2 33 E[+56]IAQDFK[+28]TDLR K79me2 
710.377548 1132.552081 b9 25 E[+56]IAQDFK[+28]TDLR K79me2 
717.385373 288.203016 y2 32 E[+56]IAQDFK[+42]TDLR K79me3 
717.385373 411.24762 y6 32 E[+56]IAQDFK[+42]TDLR K79me3 
717.385373 1146.567731 b9 27 E[+56]IAQDFK[+42]TDLR K79me3 
724.375006 288.203016 y2 40 E[+56]IAQDFK[+56]TDLR K79me0 
724.375006 950.494172 y7 23 E[+56]IAQDFK[+56]TDLR K79me0 
724.375006 1078.55275 y8 21 E[+56]IAQDFK[+56]TDLR K79me0 
731.382831 288.203016 y2 40 E[+56]IAQDFK[+70]TDLR K79me1 
731.382831 964.509822 y7 24 E[+56]IAQDFK[+70]TDLR K79me1 
731.382831 1092.5684 y8 24 E[+56]IAQDFK[+70]TDLR K79me1 
543.986018 175.118952 y1 29.7 K[+112.1]SAPATGGVK[+28]K[+56]PHR K27me0K36me2 
543.986018 616.367121 y11 23 K[+112.1]SAPATGGVK[+28]K[+56]PHR K27me0K36me2 
543.986018 695.401692 y13 19 K[+112.1]SAPATGGVK[+28]K[+56]PHR K27me0K36me2 
543.986018 962.58941 y8 25 K[+112.1]SAPATGGVK[+28]K[+56]PHR K27me0K36me2 
548.657901 241.154669 b1 17.8 K[+112.1]SAPATGGVK[+42]K[+56]PHR K27me0K36me3 
548.657901 409.230627 y3 23.8 K[+112.1]SAPATGGVK[+42]K[+56]PHR K27me0K36me3 
548.657901 623.374946 y11 23.8 K[+112.1]SAPATGGVK[+42]K[+56]PHR K27me0K36me3 
548.657901 702.409517 y13 19.8 K[+112.1]SAPATGGVK[+42]K[+56]PHR K27me0K36me3 
829.472846 241.154669 b1 33 K[+112.1]SAPATGGVK[+56]K[+56]PHR K27unmodK36unmod 
829.472846 630.364579 y11 28 K[+112.1]SAPATGGVK[+56]K[+56]PHR K27unmodK36unmod 
829.472846 1259.721881 y11 28 K[+112.1]SAPATGGVK[+56]K[+56]PHR K27unmodK36unmod 
836.480671 241.154669 b1 33 K[+112.1]SAPATGGVK[+70]K[+56]PHR K27unmodK36me1 
836.480671 637.372404 y11 29 K[+112.1]SAPATGGVK[+70]K[+56]PHR K27unmodK36me1 
836.480671 1273.737531 y11 29 K[+112.1]SAPATGGVK[+70]K[+56]PHR K27unmodK36me1 
528.29583 241.154669 b1 13 K[+112.1]STGGK[+42]APR K9me0K14Ac 
528.29583 627.357285 y6 28 K[+112.1]STGGK[+42]APR K9me0K14Ac 
528.29583 815.436992 y8 16 K[+112.1]STGGK[+42]APR K9me0K14Ac 
535.303655 241.154669 b1 13 K[+112.1]STGGK[+56]APR K9unmodK14unmod 
535.303655 742.420613 y7 18 K[+112.1]STGGK[+56]APR K9unmodK14unmod 
535.303655 829.452642 y8 18 K[+112.1]STGGK[+56]APR K9unmodK14unmod 
314.213049 175.118952 y1 18.3 K[+112.1]VLR K20unmod 
314.213049 241.154669 b1 11.3 K[+112.1]VLR K20unmod 
314.213049 387.27143 y3 11.3 K[+112.1]VLR K20unmod 
548.657901 255.170319 b1 15 K[+126.1]SAPATGGVK[+28]K[+56]PHR K27me1K36me2 
548.657901 409.230627 y3 27.8 K[+126.1]SAPATGGVK[+28]K[+56]PHR K27me1K36me2 
548.657901 616.367121 y11 20 K[+126.1]SAPATGGVK[+28]K[+56]PHR K27me1K36me2 
548.657901 695.401692 y13 18 K[+126.1]SAPATGGVK[+28]K[+56]PHR K27me1K36me2 
553.329784 255.170319 b1 17 K[+126.1]SAPATGGVK[+42]K[+56]PHR K27me1K36me3 
553.329784 593.351806 y4 26 K[+126.1]SAPATGGVK[+42]K[+56]PHR K27me1K36me3 
553.329784 623.374946 y11 23 K[+126.1]SAPATGGVK[+42]K[+56]PHR K27me1K36me3 
553.329784 702.409517 y13 19 K[+126.1]SAPATGGVK[+42]K[+56]PHR K27me1K36me3 
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836.480671 255.170319 b1 33 K[+126.1]SAPATGGVK[+56]K[+56]PHR K27me1K36unmod 
836.480671 630.364579 y11 29 K[+126.1]SAPATGGVK[+56]K[+56]PHR K27me1K36unmod 
836.480671 1259.721881 y11 30 K[+126.1]SAPATGGVK[+56]K[+56]PHR K27me1K36unmod 
843.488496 255.170319 b1 33 K[+126.1]SAPATGGVK[+70]K[+56]PHR K27me1K36me1 
843.488496 637.372404 y11 29 K[+126.1]SAPATGGVK[+70]K[+56]PHR K27me1K36me1 
843.488496 1273.737531 y11 29 K[+126.1]SAPATGGVK[+70]K[+56]PHR K27me1K36me1 
535.303655 255.170319 b1 14 K[+126.1]STGGK[+42]APR K9me1K14Ac 
535.303655 627.357285 y6 18 K[+126.1]STGGK[+42]APR K9me1K14Ac 
535.303655 815.436992 y8 18 K[+126.1]STGGK[+42]APR K9me1K14Ac 
542.31148 255.170319 b1 14 K[+126.1]STGGK[+56]APR K9me1K14unmod 
542.31148 641.372935 y6 28 K[+126.1]STGGK[+56]APR K9me1K14unmod 
542.31148 829.452642 y8 16 K[+126.1]STGGK[+56]APR K9me1K14unmod 
321.220874 175.118952 y1 19.5 K[+126.1]VLR K20me1 
321.220874 255.170319 b1 11.5 K[+126.1]VLR K20me1 
321.220874 387.27143 y3 12.5 K[+126.1]VLR K20me1 
534.654379 213.159754 b1 25.3 K[+84.1]SAPATGGVK[+28]K[+56]PHR K27me2K36me2 
534.654379 616.367121 y11 23.3 K[+84.1]SAPATGGVK[+28]K[+56]PHR K27me2K36me2 
534.654379 695.401692 y13 23.3 K[+84.1]SAPATGGVK[+28]K[+56]PHR K27me2K36me2 
534.654379 714.422093 b13 18 K[+84.1]SAPATGGVK[+28]K[+56]PHR K27me2K36me2 
539.326263 213.159754 b1 31.5 K[+84.1]SAPATGGVK[+42]K[+56]PHR K27me2K36me3 
539.326263 623.374946 y11 25.5 K[+84.1]SAPATGGVK[+42]K[+56]PHR K27me2K36me3 
539.326263 702.409517 y13 25.5 K[+84.1]SAPATGGVK[+42]K[+56]PHR K27me2K36me3 
539.326263 721.429918 b13 23.5 K[+84.1]SAPATGGVK[+42]K[+56]PHR K27me2K36me3 
543.986018 754.40938 b8 21 K[+84.1]SAPATGGVK[+56]K[+56]PHR K27me2K36me0 
543.986018 777.472984 y5 21 K[+84.1]SAPATGGVK[+56]K[+56]PHR K27me2K36me0 
543.986018 853.477794 b9 20 K[+84.1]SAPATGGVK[+56]K[+56]PHR K27me2K36me0 
548.657901 754.40938 b8 22 K[+84.1]SAPATGGVK[+70]K[+56]PHR K27me2K36me1 
548.657901 791.488634 y5 18 K[+84.1]SAPATGGVK[+70]K[+56]PHR K27me2K36me1 
548.657901 853.477794 b9 22 K[+84.1]SAPATGGVK[+70]K[+56]PHR K27me2K36me1 
514.298373 213.159754 b1 25 K[+84.1]STGGK[+42]APR K9me2K14Ac 
514.298373 685.387917 b6 23 K[+84.1]STGGK[+42]APR K9me2K14Ac 
514.298373 815.436992 y8 26 K[+84.1]STGGK[+42]APR K9me2K14Ac 
521.306198 213.159754 b1 25 K[+84.1]STGGK[+56]APR K9me2K14unmod 
521.306198 641.372935 y6 35 K[+84.1]STGGK[+56]APR K9me2K14unmod 
521.306198 829.452642 y8 25 K[+84.1]STGGK[+56]APR K9me2K14unmod 
300.215592 175.118952 y1 19.9 K[+84.1]VLR k20me2 
300.215592 213.159754 b1 22 K[+84.1]VLR k20me2 
300.215592 387.27143 y3 17.9 K[+84.1]VLR k20me2 
539.326263 616.367121 y11 20 K[+98.1]SAPATGGVK[+28]K[+56]PHR K27me3K36me2 
539.326263 721.429918 b13 23.5 K[+98.1]SAPATGGVK[+28]K[+56]PHR K27me3K36me2 
539.326263 768.42503 b8 22 K[+98.1]SAPATGGVK[+28]K[+56]PHR K27me3K36me2 
539.326263 867.493444 b9 20 K[+98.1]SAPATGGVK[+28]K[+56]PHR K27me3K36me2 
548.657901 768.42503 b8 22 K[+98.1]SAPATGGVK[+56]K[+56]PHR  
548.657901 777.472984 y5 22 K[+98.1]SAPATGGVK[+56]K[+56]PHR K27me3K36unmod 
548.657901 867.493444 b9 20 K[+98.1]SAPATGGVK[+56]K[+56]PHR K27me3K36unmod      
553.329784 768.42503 b8 22 K[+98.1]SAPATGGVK[+70]K[+56]PHR K27me3K36me1      
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553.329784 791.488634 y5 18 K[+98.1]SAPATGGVK[+70]K[+56]PHR K27me3K36me1 
553.329784 867.493444 b9 22 K[+98.1]SAPATGGVK[+70]K[+56]PHR K27me3K36me1 
521.306198 529.298038 b5 24 K[+98.1]STGGK[+42]APR K9me3K14Ac 
521.306198 570.335821 y5 24 K[+98.1]STGGK[+42]APR K9me3K14Ac 
521.306198 815.436992 y8 25 K[+98.1]STGGK[+42]APR K9me3K14Ac 
528.314023 641.372935 y6 28 K[+98.1]STGGK[+56]APR K9me3K14unmod 
528.314023 784.45633 b7 28 K[+98.1]STGGK[+56]APR K9me3K14unmod 
528.314023 829.452642 y8 24 K[+98.1]STGGK[+56]APR K9me3K14unmod 
307.223417 175.118952 y1 19 K[+98.1]VLR K20me3 
307.223417 387.27143 y3 15 K[+98.1]VLR K20me3 
307.223417 439.327882 b3 16 K[+98.1]VLR K20me3 
521.288005 227.139019 b1 18 K[+98]STGGK[+42]APR K9AcK14Ac 
521.288005 728.404963 y7 12 K[+98]STGGK[+42]APR K9AcK14Ac 
521.288005 815.436992 y8 25 K[+98]STGGK[+42]APR K9AcK14Ac 
528.29583 227.139019 b1 18 K[+98]STGGK[+56]APR K9AcK14unmod 
528.29583 641.372935 y6 28 K[+98]STGGK[+56]APR K9AcK14unmod 
528.29583 829.452642 y8 15 K[+98]STGGK[+56]APR K9AcK14unmod 
748.928894 501.274132 b4 29 V[+56]TIMPK[+56]DIQLAR VTIMPKDIQLAR 
748.928894 996.583656 y8 29 V[+56]TIMPK[+56]DIQLAR VTIMPKDIQLAR 
748.928894 1127.624141 y9 29 V[+56]TIMPK[+56]DIQLAR VTIMPKDIQLAR 
681.88501 744.461415 y6 25.5 Y[+56]QK[+56]STELLIR YQKSTELLIR 
681.88501 831.493444 y7 25.5 Y[+56]QK[+56]STELLIR YQKSTELLIR 
681.88501 1015.614622 y8 25.5 Y[+56]QK[+56]STELLIR YQKSTELLIR 
544.81419 376.197931 b2 22 Y[+56]RPGTVALR YRPGTVALR 
544.81419 713.43045 y7 22 Y[+56]RPGTVALR YRPGTVALR 
544.81419 801.425364 b7 25 Y[+56]RPGTVALR YRPGTVALR 
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Figure 4.1 Experimental procedure analyzing histone modifications from senescent 
cells 
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Figure 4.2 Reduction of global histone acetylation in senescent cells. 
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Figure 4.3 Decreased acetylation level on N-terminal peptide of histone H4 in 
senescent cells. 
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Figure 4.4 Protein expression level of selected HDACs did not change in senescent 
cells. 
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Figure 4.5 Decreased acetylation on H2AK15 in senescent cells. (A) ProSight output 
of peptide identification. (B) Fragmentation spectrum for peptide identification of the 
K15Ac peptide (A12-R17). (C) Quantitation of acetylation level on H2AK15. 
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Figure 4.6 (A) Methylation pattern changes on histone H3K27 in senescent cells. (B) 
Methylation pattern changes on histone H3K36 in senescent cells. 
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Figure 4.7 Methylation pattern of histone H3K79 (A) and H3K9 (B) in senescent cells. 
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Chapter 5. Conclusions 
 
Post-translational modifications on histone proteins have been known to be 
important in gene regulation and altered global histone modification patterns have 
been correlated to different cancers or cancer stages [1]. They have also been shown 
to predict patient outcome in human carcinoma [2]. Our recent technological 
developments in top down mass spectrometry (MS) using LC-FTICR MS provide a 
useful tool for quickly assessing global histone modification patterns in human cells 
with the ability to distinguish different protein expression levels of histone isoforms 
and comparing modification changes upon perturbation of histone modifying enzymes. 
This methodology can also be used for cell based HDAC or HAT inhibitor screening. 
Complementary to the intact histone profiling with top down MS, a newly 
developed approach using chemical reactions to modify histone proteins followed by 
trypsin digestion and selected reaction monitoring in a triple-quadrupole MS allows 
us to precisely quantify global methylation occupancy on different lysine residues of 
histone H3.  
Combining these two methodologies, we have found an altered global histone 
modification pattern in oncogene-induced senescent cells. Oncogene-induced 
senescence is a mechanism of tumor suppression that restricts the progression of 
benign tumors. Early studies have shown that a specific chromatin structure termed as 
senescence associated heterochromatin is formed in OIS cells. This chromatin 
structure has thought to be involved in repressing E2F responsive genes. Our MS 
based global histone modification analysis revealed a decreased total acetylation level 
on all core histone proteins in OIS cells along with increased histone H3 K27 di- and 
tri-methylation and decreased histone H3 K36 di- and tri-methylation. As histone 
H3K27 methylation is generally related to heterochromatin formation and histone 
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H3K36 methylation is usually involved in transcriptional elongation, it suggested that 
this global histone modification pattern might correlate to a global heterochromatin 
formation or chromatin condensation in addition to heterochromatin formation at 
specific genomic loci. With more information from the genome wide approaches, 
such as Chip-Seq, in the future, it will become more clear how much local chromatin 
modifications and global chromatin structures contribute to the maintenance of 
senescence state and how chromatin remodelers function to mediate cellular 
senescence. 
Protein expression level changes determined by SILAC indicate that decreased 
abundance of proteins involved in glycolysis and increased protein expression level 
on oxidative phosphorylation in OIS cells is opposite of the „Warburg effect‟. In 
senescent cells, the expression level of PDH is slightly increased while the 
phosphorylated form is significantly decreased. This decreased phosphorylation of 
PDH was likely because one of the PDH kinases, PDK-1‟s expression level, 
decreased in senescent cells. Manipulated cell metabolism mimicking the profile by 
knocking down PDK-1 and limiting glycolysis is able to trigger senescence phenotype. 
This suggested that altered primary metabolism was not only a part of senescence 
phenotype but also contributed to the cellular senescence program.  
By further studying the underlying mechanism controlling the molecular 
switch of the metabolic profiles it could be of great importance to investigate how 
cancers, if required as part of the mechanism, disrupt the metabolism control and 
hence bypass senescence. Since hypoxia-inducible factor 1 (HIF1) has been 
implicated in regulating a set of genes that are responsible for cell metabolism, 
including PDK-1 and glycolytic enzymes, understanding how HIF1 is regulated in 
senescent cells would further help explain how such metabolic switch is made in 
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senescent cells. Other proteins or mechanisms which could regulate the expression 
level or activity of PDK-1 could also provide insights understanding the metabolic 
switch in senescent cells.  
If such a metabolic program to prevent tumorigenesis exits in normal cells, it 
would be important to understand the precise mechanisms how cancer cells disrupt it. 
Restoration of the innate program in cancer cells could be beneficial for cancer 
therapy. 
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APPENDIX A. TABLE OF UPREGULATED PROTEINS FROM QUANTITATIVE 
PROTEOMICS 
 
Protein Name Ratio (S/C) S.D. 
39S ribosomal protein L20, mitochondrial 2.5  
40S ribosomal protein S11 2.5 1.8 
40S ribosomal protein S15a 2.1  
40S ribosomal protein S25 2.2  
40S ribosomal protein S3a 2.2  
60 kDa heat shock protein, mitochondrial;Heat shock protein 60;60 
kDa chaperonin;Chaperonin 60;Mitochondrial matrix protein P1;P60 
lymphocyte protein;HuCHA60 2.2  
60S acidic ribosomal protein P0;L10E;60S acidic ribosomal protein 
P0-like;cDNA FLJ51469, highly similar to 60S acidic ribosomal protein 
P0;RPLP0 protein 2 0.8 
60S ribosomal protein L8;cDNA FLJ53750, highly similar to 60S 
ribosomal protein L8 2.1  
Acetyl-CoA acetyltransferase, mitochondrial;Acetoacetyl-CoA 
thiolase;T2;ACAT1 protein 2.5  
Acyl-CoA dehydrogenase family member 9, mitochondrial;cDNA 
FLJ12506 fis, clone NT2RM2001700, weakly similar to ACYL-COA 
DEHYDROGENASE, VERY-LONG-CHAIN SPECIFIC (EC 1.3.99.-
);cDNA FLJ53144, highly similar to Acyl-CoA dehydrogenase family 
member 9, mitochondrial (EC 1.3.99.-);Acyl-Coenzyme A 
dehydrogenase family, member 9, isoform CRA_b;ACAD9 protein 2.1  
Acylglycerol kinase, mitochondrial;Multiple substrate lipid kinase 2.5  
Adenylyl cyclase-associated protein 2.2  
ADP/ATP translocase 3;Adenine nucleotide translocator 2;ANT 
3;ADP,ATP carrier protein 3;Solute carrier family 25 member 
6;ADP,ATP carrier protein, isoform T2 2 0.5 
Alpha-mannosidase 2;Alpha-mannosidase II;Mannosyl-
oligosaccharide 1,3-1,6-alpha-mannosidase;Golgi alpha-
mannosidase II;Mannosidase alpha class 2A member 1 2.2  
Annexin A1;Annexin-1;Annexin I;Lipocortin I;Calpactin 
II;Chromobindin-9;p35;Phospholipase A2 inhibitory protein 2.2 0.1 
Apoptosis-inducing factor 1, mitochondrial;Programmed cell death 
protein 8;Apoptosis-inducing factor short isoform 1 2.1  
Arginyl-tRNA synthetase, cytoplasmic;Arginine--tRNA ligase 2.1  
Asparaginyl-tRNA synthetase, cytoplasmic;Asparagine--tRNA ligase 2  
Aspartate aminotransferase, mitochondrial;mAspAT;Transaminase 
A;Glutamate oxaloacetate transaminase 2;Fatty acid-binding 
protein;FABP-1;FABPpm;Aspartate aminotransferase 2 0.3 
ATP synthase subunit alpha, mitochondrial;ATP synthase subunit 
alpha 2.2 1.7 
ATP synthase subunit b, mitochondrial 4.6  
ATP synthase subunit beta, mitochondrial 2.2 1.4 
ATP synthase subunit d, mitochondrial 3.8  
ATP synthase subunit g, mitochondrial 2 0.1 
ATP synthase subunit gamma, mitochondrial;F-ATPase gamma 
subunit 2.2 0.9 
ATP synthase subunit O, mitochondrial;Oligomycin sensitivity 
conferral protein;ATP synthase 3.8  
ATPase family AAA domain-containing protein 3A;cDNA FLJ31537 
fis, clone NT2RI2000704, highly similar to ATPase family AAA 
domain-containing protein 3A;ATPase family AAA domain-containing 
protein 3B;TOB3;Putative uncharacterized protein ATAD3B;ATPase 
family AAA domain-containing protein 3C 2 0.8 
Barrier-to-autointegration factor;Breakpoint cluster region protein 1 2.7  
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Bifunctional aminoacyl-tRNA synthetase;Proliferation-inducing gene 
32 protein;Glutamyl-tRNA synthetase;Glutamate--tRNA ligase;Prolyl-
tRNA synthetase;Proline--tRNA ligase 2  
C-1-tetrahydrofolate synthase, cytoplasmic;Methylenetetrahydrofolate 
dehydrogenase;Methenyltetrahydrofolate 
cyclohydrolase;Formyltetrahydrofolate synthetase 2  
Calcium/calmodulin-dependent protein kinase type II delta 
chain;cDNA FLJ31080 fis, clone HSYRA2001615, highly similar to 
Calcium/calmodulin-dependent protein kinase type II delta chain (EC 
2.7.11.17);Putative uncharacterized protein CAMK2D;CAMK2D 
protein 2.8  
Calcium-binding mitochondrial carrier protein Aralar1;Mitochondrial 
aspartate glutamate carrier 1;Solute carrier family 25 member 
12;Putative uncharacterized protein SLC25A12 2.4 0.1 
Caldesmon 2.4 2.3 
cDNA FLJ25678 fis, clone TST04067, highly similar to PURINE 
NUCLEOSIDE PHOSPHORYLASE (EC 2.4.2.1);Purine nucleoside 
phosphorylase;Inosine phosphorylase 2  
cDNA FLJ31740 fis, clone NT2RI2007133, highly similar to Zinc 
finger protein 595;Zinc finger protein 595 10  
cDNA FLJ51906, highly similar to Heat-shock protein beta-6 3.5  
cDNA FLJ58045, highly similar to NADH dehydrogenase (ubiquinone) 
1 alpha subcomplex subunit 13 (EC 1.6.5.3);NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 13;NADH-ubiquinone 
oxidoreductase B16.6 subunit;Complex I-B16.6;Gene associated with 
retinoic-interferon-induced mortality 19 protein;Cell death regulatory 
protein GRIM-19;cDNA FLJ57958, highly similar to NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 13 (EC 
1.6.5.3) 3.2  
cDNA FLJ59473, highly similar to InaD-like protein;InaD-like 
protein;Pals1-associated tight junction protein;Protein associated to 
tight junctions 4.5 5.0 
cDNA FLJ61248, highly similar to Glycerol kinase, testis specific 1 
(EC 2.7.1.30);Glycerol kinase;ATP:glycerol 3-
phosphotransferase;Glycerokinase;Putative uncharacterized protein 
GK;Putative glycerol kinase 3;Glycerol kinase, testis specific 1 2.8  
Coagulation factor V;Activated protein C cofactor;Proaccelerin, labile 
factor;Coagulation factor V heavy chain;Coagulation factor V light 
chain 7.3  
Coatomer subunit alpha;Alpha-coat protein;HEP-
COP;Xenin;Xenopsin-related peptide;Proxenin 2.1  
Collagen alpha-1(I) chain;Alpha-1 type I collagen 2.2 0.4 
Cytochrome b-c1 complex subunit 7;Ubiquinol-cytochrome c 
reductase complex 14 kDa protein;Complex III subunit 7;Complex III 
subunit VII;QP-C 2 0.7 
Cytochrome c oxidase subunit 5A, mitochondrial;Cytochrome c 
oxidase polypeptide Va 2.2  
Cytochrome c oxidase subunit 5B, mitochondrial;Cytochrome c 
oxidase polypeptide Vb 2 0.7 
Cytochrome c1, heme protein, mitochondrial;Ubiquinol-cytochrome-c 
reductase complex cytochrome c1 subunit;Cytochrome b-c1 complex 
subunit 4;Complex III subunit 4;Complex III subunit IV 2 0.1 
Cytoskeleton-associated protein 4;63 kDa membrane 
protein;p63;Similar to cytoskeleton-associated protein 4 2 0.8 
DENN domain-containing protein 5B;RAB6IP1-like protein 5  
DERP12 (Dermal papilla derived protein 12) 4.4 4.0 
Desmoglein-4 6.8  
Desmoplakin;250/210 kDa paraneoplastic pemphigus antigen 3.4  
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 2.3  
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dehydrogenase complex, mitochondrial;Pyruvate dehydrogenase 
complex E2 subunit;Dihydrolipoamide S-acetyltransferase component 
of pyruvate dehydrogenase complex;70 kDa mitochondrial 
autoantigen of primary biliary cirrhosis;M2 antigen complex 70 kDa 
subunit;cDNA FLJ57320, highly similar to Dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate dehydrogenase complex, 
mitochondrial (EC 2.3.1.12) 
Dihydropyridine receptor alpha 2 subunit;Voltage-dependent calcium 
channel subunit alpha-2/delta-1;Voltage-gated calcium channel 
subunit alpha-2/delta-1;Voltage-dependent calcium channel subunit 
alpha-2-1;Voltage-dependent calcium channel subunit delta-1 2.9  
DNA-dependent protein kinase catalytic subunit;DNPK1;p460 2 0.1 
Drug-sensitive protein 1;Gastric-associated differentially-expressed 
protein YA61P 5.4 3.1 
Elongation factor 1-beta 2.1  
Endoglin 2.3  
Endoplasmic reticulum protein ERp29;ERp31;ERp28 2.1  
Eukaryotic translation initiation factor 3, subunit E interacting 
protein;Eukaryotic translation initiation factor 3 subunit L;Eukaryotic 
translation initiation factor 3 subunit E-interacting protein;Eukaryotic 
translation initiation factor 3 subunit 6-interacting protein;cDNA 
FLJ59381, highly similar to Eukaryotic translation initiation factor 3 
subunit 6-interacting protein;cDNA FLJ36221 fis, clone 
THYMU2000950, highly similar to Eukaryotic translation initiation 
factor 3 subunit 6-interacting protein;Eukaryotic translation initiation 
factor 3, subunit 6 interacting protein, isoform CRA_a 2.2 1.3 
Eukaryotic translation initiation factor 4 gamma 1;p220;EIF4G1 
protein 2 1.6 
Exportin-1;Chromosome region maintenance 1 protein 
homolog;cDNA FLJ42779 fis, clone BRAWH3005300, highly similar 
to Exportin-1 3.2  
Far upstream element-binding protein 3 9.6  
Fatty acid synthase;[Acyl-carrier-protein] S-acetyltransferase;[Acyl-
carrier-protein] S-malonyltransferase;3-oxoacyl-[acyl-carrier-protein] 
synthase;3-oxoacyl-[acyl-carrier-protein] reductase;3-
hydroxypalmitoyl-[acyl-carrier-protein] dehydratase;Enoyl-[acyl-
carrier-protein] reductase;Oleoyl-[acyl-carrier-protein] hydrolase 2.5 1.1 
Fibronectin;Cold-insoluble globulin;Ugl-Y1;Ugl-Y2;Ugl-Y3 2.6 1.3 
FUS-interacting serine-arginine-rich protein 1;TLS-associated protein 
with Ser-Arg repeats;TLS-associated serine-arginine protein;40 kDa 
SR-repressor protein;Splicing factor SRp38;cDNA FLJ58902, highly 
similar to FUS-interacting serine-arginine-rich protein1;FUS 
interacting protein (Serine/arginine-rich) 1;FUSIP1 protein 2.2  
Glutaminyl-tRNA synthetase;Glutamine--tRNA ligase;cDNA 
FLJ54453, highly similar to Glutaminyl-tRNA synthetase (EC 
6.1.1.18);Glutaminyl-tRNA synthetase, isoform CRA_a;cDNA 
FLJ54487, highly similar to Glutaminyl-tRNA synthetase (EC 
6.1.1.18);cDNA FLJ54881, highly similar to Glutaminyl-tRNA 
synthetase (EC 6.1.1.18) 2.8  
Glycogen phosphorylase, brain form 2.3 0.4 
Golgi apparatus protein 1;Golgi sialoglycoprotein MG-160;E-selectin 
ligand 1;Cysteine-rich fibroblast growth factor receptor;CFR-1 2.6 1.9 
Golgi integral membrane protein 4;Golgi phosphoprotein 4;Golgi 
integral membrane protein, cis;Golgi-localized phosphoprotein of 130 
kDa 2.7  
Heterochromatin protein 1-binding protein 3;Protein HP1-
BP74;Heterochromatin protein 1, binding protein 3 2.3  
Heterogeneous nuclear ribonucleoprotein A/B;APOBEC1-binding 
protein 1;Putative uncharacterized protein HNRNPAB 2.2 1.4 
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Heterogeneous nuclear ribonucleoprotein A0 2.1 1.5 
Heterogeneous nuclear ribonucleoprotein D-like;JKT41-binding 
protein;AU-rich element RNA-binding factor;Protein laAUF1 2.5  
Heterogeneous nuclear ribonucleoprotein K;Transformation up-
regulated nuclear protein;cDNA FLJ54552, highly similar to 
Heterogeneous nuclear ribonucleoprotein K;cDNA FLJ39066 fis, 
clone NT2RP7014743, highly similar to HETEROGENEOUS 
NUCLEAR RIBONUCLEOPROTEIN K;cDNA FLJ41122 fis, clone 
BRACE2013911, highly similar to HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN K 2.1 2.2 
Heterogeneous nuclear ribonucleoprotein M 2.1 1.6 
Histone H2A;Histone H2A.x;Histone H2A type 1-A;H2A/r;Histone H2A 
type 1;Histone H2A type 1-B/E;H2A/m;H2A.2;H2A/a;Histone H2A 
type 1-C;H2A/l;Histone H2A type 2-A;H2A/o;Histone H2A type 
3;Histone H2A type 1-D;H2A.3;H2A/g;Histone H2A type 2-B;Histone 
H2A type 2-C;H2A-GL101;H2A/q;Histone H2A.J;Histone H2A type 1-
H;H2A/s;Histone H2A type 1-J;Histone H2A.Z;Histone 
H2A.V;H2A.F/Z 2.9  
Histone H2B type 1-N;H2B.d;H2B/d;Histone H2B;Histone H2B type 1-
K;HIRA-interacting protein 1;Histone H2B type 2-F;Histone H2B type 
1-H;H2B.j;H2B/j;Histone H2B type 1-L;H2B.c;H2B/c;Histone H2B type 
1-C/E/F/G/I;H2B.a/g/h/k/l;H2B.1 A;H2B/g;H2B/h;H2B/k;H2B/l;Histone 
H2B type 1-D;H2B.b;H2B/b;H2B.1 B;HIRA-interacting protein 
2;Histone H2B type F-S;Histone H2B type 1-M;HIST1H2BC 
protein;Histone H2B type 3-B;H2B type 12;Histone H2B type 2-
E;H2B.q;H2B/q;H2B-GL105;Histone H2B type 1-
J;H2B.r;H2B/r;H2B.1;Histone H2B type 1-
O;H2B.n;H2B/n;H2B.2;Histone H2B type 1-B;H2B.f;H2B/f;Histone 
H2B type 1-A;Histone H2B, testis;Testis-specific histone H2B 2.5  
Histone H4 3 2.1 
Inhibitor of nuclear factor kappa-B kinase-interacting protein 2.3 0.2 
Inorganic pyrophosphatase;Pyrophosphate phospho-
hydrolase;Pyrophosphatase (Inorganic) 1 2.1  
Integrin alpha-2;Platelet membrane glycoprotein Ia;Collagen 
receptor;VLA-2 alpha chain;CD49 antigen-like family member B 2  
Integrin alpha-3;Galactoprotein B3;VLA-3 alpha chain;FRP-2;CD49 
antigen-like family member C;Integrin alpha-3 heavy chain;Integrin 
alpha-3 light chain 3.4  
Interleukin enhancer-binding factor 3;Nuclear factor of activated T-
cells 90 kDa;Double-stranded RNA-binding protein 76;Translational 
control protein 80;Nuclear factor associated with dsRNA;M-phase 
phosphoprotein 4;Interleukin enhancer binding factor 3 isoform c 
variant 2.4 1.8 
Isoleucyl-tRNA synthetase, cytoplasmic;Isoleucine--tRNA ligase;IARS 
protein 2.6  
Isoleucyl-tRNA synthetase, mitochondrial;Isoleucine--tRNA ligase 2.8  
Kinesin heavy chain isoform 5C;Kinesin heavy chain neuron-specific 
2;Kinesin heavy chain isoform 5A;Neuronal kinesin heavy 
chain;Kinesin heavy chain neuron-specific 1;Kinesin-1 heavy 
chain;Ubiquitous kinesin heavy chain;Conventional kinesin heavy 
chain 4.4  
Kinesin-like protein KIF14 6.4  
Leptin;Obesity factor;Obese protein 13.8  
Leucine-rich PPR motif-containing protein, mitochondrial;130 kDa 
leucine-rich protein;LRP 130;GP130 2.1 0.8 
Lymphoid-restricted membrane protein;Protein Jaw1;Processed 
lymphoid-restricted membrane protein 114  
Lysophospholipid acyltransferase 7;1-acylglycerophosphatidylinositol 
O-acyltransferase;Lysophosphatidylinositol acyltransferase;Leukocyte 2.3  
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receptor cluster member 4;Bladder and breast carcinoma-
overexpressed gene 1 protein;Membrane-bound O-acyltransferase 
domain-containing protein 7;Putative uncharacterized protein 
MBOAT7;Leukocyte receptor cluster (LRC) member 4 
Malate dehydrogenase, cytoplasmic;Cytosolic malate dehydrogenase 2 1.6 
Malate dehydrogenase, mitochondrial 2.4 1.4 
Mitochondrial carrier homolog 1;Presenilin-associated protein;CGI-64 
protein;Mitochondrial carrier homolog 1 (C. elegans) 2.1  
Mitochondrial fission 1 protein;Fis1 homolog;Tetratricopeptide repeat 
protein 11;TPR repeat protein 11 2.1  
Mitochondrial import receptor subunit TOM22 homolog;Translocase 
of outer membrane 22 kDa subunit homolog;1C9-2 2.9  
Mitochondrial import receptor subunit TOM40 homolog;Translocase 
of outer membrane 40 kDa subunit homolog;Protein Haymaker;p38.5 2 0.4 
Mitochondrial import receptor subunit TOM6 homolog;Translocase of 
outer membrane 6 kDa subunit homolog;Overexpressed breast tumor 
protein 3  
Mitochondrial inner membrane protein;Mitofilin;p87/89;Cell 
proliferation-inducing gene 4 protein;cDNA FLJ59418, highly similar 
to Mitochondrial inner membrane protein 2.2 1.1 
Mitochondrial ribosomal protein L10, isoform CRA_b;Putative 
uncharacterized protein MRPL10;cDNA FLJ45232 fis, clone 
BRCAN2021718, highly similar to Homo sapiens mitochondrial 
ribosomal protein L10 (MRPL10), mRNA;39S ribosomal protein L10, 
mitochondrial;MRP-L8 2.4  
Mitogen-activated protein kinase kinase kinase kinase 1;MAPK/ERK 
kinase kinase kinase 1;Hematopoietic progenitor kinase;Mitogen-
activated protein kinase kinase kinase kinase 1, isoform 
CRA_b;Putative uncharacterized protein MAP4K1 14.6  
Myb-binding protein 1A;cDNA FLJ57836, highly similar to Myb-
binding protein 1A 2 1.0 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 
4;NADH-ubiquinone oxidoreductase MLRQ subunit;Complex I-MLRQ 2.4 0.7 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 
5;NADH-ubiquinone oxidoreductase 13 kDa-B subunit;Complex I-
13kD-B;Complex I subunit B13;Putative uncharacterized protein 
DKFZp781K1356 2 1.0 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, 
mitochondrial;NADH-ubiquinone oxidoreductase 39 kDa 
subunit;Complex I-39kD 2.1 0.3 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 
4;NADH-ubiquinone oxidoreductase B15 subunit;Complex I-
B15;NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 4, 
15kDa 2.03 0.9 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial;NADH-ubiquinone oxidoreductase 24 kDa 
subunit;Putative uncharacterized protein ENSP00000343430 2.06 1.1 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial;NADH-ubiquinone oxidoreductase 49 kDa 
subunit;Complex I-49kD 2.2  
NADH dehydrogenase [ubiquinone] iron-sulfur protein 5;NADH-
ubiquinone oxidoreductase 15 kDa subunit;Complex I-15 kDa 2.6  
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, 
mitochondrial;NADH-ubiquinone oxidoreductase 23 kDa 
subunit;Complex I-23kD;TYKY subunit;cDNA FLJ57061, highly 
similar to NADH-ubiquinone oxidoreductase 23 kDa subunit, 
mitochondrial (EC 1.6.5.3) 2.1 1.2 
NADH-cytochrome b5 reductase 1;NAD(P)H:quinone oxidoreductase 
type 3 polypeptide A2;Humb5R2 3.3  
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NADH-cytochrome b5 reductase 3;Diaphorase-1;NADH-cytochrome 
b5 reductase 3 membrane-bound form;NADH-cytochrome b5 
reductase 3 soluble form;Cytochrome b5 reductase 3 2.3  
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial;Complex I-75kD 2 0.8 
Nestin;NES protein 2.3 0.6 
Nucleophosmin;Nucleolar phosphoprotein B23;Numatrin;Nucleolar 
protein NO38;Nucleophosmin (Nucleolar phosphoprotein B23, 
numatrin);Nucleophosmin/B23.2 2.5 1.3 
OCIA domain-containing protein 1;Ovarian carcinoma 
immunoreactive antigen 2.1 1.2 
PABPC4 protein;Polyadenylate-binding protein 4;Inducible poly(A)-
binding protein;Activated-platelet protein 1;Polyadenylate-binding 
protein 1;cDNA FLJ37875 fis, clone BRSSN2018771, highly similar to 
Poly(A)-binding protein 1;Poly(A) binding protein, cytoplasmic 4 
(Inducible form);Poly(A) binding protein, cytoplasmic 4 (Inducible 
form), isoform CRA_e;cDNA FLJ59219, highly similar to Poly(A)-
binding protein 1 2.1  
Phenylalanyl-tRNA synthetase beta chain;Phenylalanine--tRNA ligase 
beta chain 2.6 1.7 
Phosphate carrier protein, mitochondrial;Phosphate transport 
protein;Solute carrier family 25 member 3;cDNA FLJ90278 fis, clone 
NT2RP1000325, highly similar to Phosphate carrier protein, 
mitochondrialprecursor 2.2 0.9 
Phosphoserine aminotransferase;Phosphohydroxythreonine 
aminotransferase 2.3  
Plasminogen activator inhibitor 2;Placental plasminogen activator 
inhibitor;Monocyte Arg-serpin;Urokinase inhibitor 2.1  
Poly(U)-binding-splicing factor PUF60;60 kDa poly(U)-binding-splicing 
factor;FUSE-binding protein-interacting repressor;Siah-binding 
protein 1;Ro-binding protein 1 3.5  
Polyadenylate-binding protein 1;cDNA FLJ37875 fis, clone 
BRSSN2018771, highly similar to Poly(A)-binding protein 1;PABPC4 
protein;Polyadenylate-binding protein 4;Inducible poly(A)-binding 
protein;Activated-platelet protein 1;Poly(A) binding protein, 
cytoplasmic 4 (Inducible form);Poly(A) binding protein, cytoplasmic 4 
(Inducible form), isoform CRA_e;cDNA FLJ59219, highly similar to 
Poly(A)-binding protein 1;Polyadenylate-binding protein 3;Testis-
specific poly(A)-binding protein 2 2.0 
Polymerase I and transcript release factor 2.4  
Pre-mRNA branch site protein p14;SF3B 14 kDa subunit 2.1  
Probable ATP-dependent RNA helicase DDX5;DEAD box protein 
5;RNA helicase p68;cDNA FLJ59339, highly similar to Probable ATP-
dependent RNA helicase DDX5 (EC 3.6.1.-) 2.4 1.3 
Prohibitin;Prohibitin variant;Putative uncharacterized protein PHB 2.1 0.6 
Prohibitin-2;B-cell receptor-associated protein BAP37;Repressor of 
estrogen receptor activity;D-prohibitin;cDNA FLJ56579, highly similar 
to Prohibitin-2 2.3 0.9 
Proline-, glutamic acid- and leucine-rich protein 1;Modulator of non-
genomic activity of estrogen receptor;Transcription factor 
HMX3;Putative uncharacterized protein PELP1 2.5 1.5 
Proteasome activator complex subunit 4;Proteasome activator PA200 2.3  
Protein FAM98A;Family with sequence similarity 98, member 
A;FAM98A protein;cDNA FLJ38868 fis, clone MESAN2013211, highly 
similar to Protein FAM98A 5.1  
Protein KIAA1967;Deleted in breast cancer gene 1 protein;p30 DBC 201 1.8 
Protein S100-A13;S100 calcium-binding protein A13 2 0.3 
Protein S100-A3;S100 calcium-binding protein A3 4  
Protein transport protein Sec31A;SEC31-related protein A;SEC31-like 2.2  
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1;ABP125;ABP130;Web1-like protein 
Protein-glutamine gamma-glutamyltransferase E;Transglutaminase-
3;Protein-glutamine gamma-glutamyltransferase E 50 kDa non-
catalytic chain;Protein-glutamine gamma-glutamyltransferase E 27 
kDa catalytic chain;cDNA FLJ56823, highly similar to Protein-
glutamine gamma-glutamyltransferase E (EC 2.3.2.13);cDNA 
FLJ57574, highly similar to Protein-glutamine gamma-
glutamyltransferase E (EC 2.3.2.13) 4.1  
Putative uncharacterized protein DBN1;Drebrin;Developmentally-
regulated brain protein 2.1 0.4 
Putative uncharacterized protein DKFZp686P03159;Annexin 
A2;Annexin-2;Annexin II;Lipocortin II;Calpactin I heavy 
chain;Chromobindin-8;p36;Protein I;Placental anticoagulant protein 
IV;Putative annexin A2-like protein;Annexin A2 pseudogene 
2;Lipocortin II pseudogene;cDNA FLJ59138, highly similar to Annexin 
A2;cDNA FLJ34687 fis, clone MESAN2000620, highly similar to 
Annexin A2 2.1 1.2 
Putative uncharacterized protein EIF3CL;Eukaryotic translation 
initiation factor 3 subunit C;Eukaryotic translation initiation factor 3 
subunit 8;eIF3 p110;cDNA FLJ53378, highly similar to Eukaryotic 
translation initiation factor 3 subunit 8;cDNA FLJ55750, highly similar 
to Eukaryotic translation initiation factor 3 subunit 8 2 0.8 
Putative uncharacterized protein EIF3D;Eukaryotic translation 
initiation factor 3 subunit D;Eukaryotic translation initiation factor 3 
subunit 7;eIF-3-zeta;eIF3 p66 2.3 1.6 
Putative uncharacterized protein MATR3;Matrin-3 2.1 2.2 
Putative uncharacterized protein NACA;Nascent polypeptide-
associated complex subunit alpha;Alpha-NAC;cDNA FLJ53704, 
moderately similar to Nascent polypeptide-associated complex 
subunit alpha 2 0.5 
Putative uncharacterized protein RPL7P23;Putative uncharacterized 
protein RPL7;60S ribosomal protein L7;Similar to 60S ribosomal 
protein L7; similar to P18124 (PID:d133021) 2  
Putative uncharacterized protein SAMM50;Sorting and assembly 
machinery component 50 homolog 3  
Putative uncharacterized protein SFXN3;Sideroflexin 3;Sideroflexin-3 3.1  
Putative uncharacterized protein;Calpain-5;New calpain 3;htra-
3;cDNA FLJ36831 fis, clone ASTRO2010615, highly similar to 
Calpain-5 (EC 3.4.22.-) 77  
Ras GTPase-activating protein-binding protein 1;G3BP-1;ATP-
dependent DNA helicase VIII;HDH-VIII;GAP SH3 domain-binding 
protein 1;CDNA FLJ26493 fis, clone KDN06317, highly similar to Ras-
GTPase-activating protein binding protein 1 2.2 1.0 
Ras GTPase-activating protein-binding protein 2;G3BP-2;GAP SH3 
domain-binding protein 2 2.7  
Regulator of microtubule dynamics protein 3;Protein 
FAM82A2;Protein FAM82C;Protein tyrosine phosphatase-interacting 
protein 51;TCPTP-interacting protein 51;Cerebral protein 10 2.6 2.3 
Reticulon-3;Neuroendocrine-specific protein-like 2;NSP-like protein II 2.2  
rRNA 2'-O-methyltransferase fibrillarin;34 kDa nucleolar scleroderma 
antigen 2.3  
Scaffold attachment factor B2;SAFB protein;Scaffold attachment 
factor B;Scaffold attachment factor B1;SAB-B1;SAF-B;HSP27 
estrogen response element-TATA box-binding protein;Putative 
uncharacterized protein SAFB2 3.2  
SDHA protein;Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial;Flavoprotein subunit of complex II;cDNA 
FLJ16373 fis, clone THYMU3000269, highly similar to Succinate 
dehydrogenase (ubiquinone) flavoprotein subunit, mitochondrial (EC 2.5  
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1.3.5.1) 
Sideroflexin-1;Tricarboxylate carrier protein 2 0.6 
Splicing factor 3 subunit 1;Spliceosome-associated protein 
114;SF3a120 2.4  
Splicing factor 3B subunit 1;Pre-mRNA-splicing factor SF3b 155 kDa 
subunit;Spliceosome-associated protein 155 2 1.4 
Splicing factor U2AF 65 kDa subunit;U2 auxiliary factor 65 kDa 
subunit;U2 snRNP auxiliary factor large subunit 2 1.4 
Splicing factor, arginine/serine-rich 1;pre-mRNA-splicing factor SF2, 
P33 subunit;Alternative-splicing factor 1 2.2  
Splicing factor, proline- and glutamine-rich;Polypyrimidine tract-
binding protein-associated-splicing factor;DNA-binding p52/p100 
complex, 100 kDa subunit;100 kDa DNA-pairing protein 2.3 1.5 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial;Flavoprotein subunit of complex II;SDHA protein 5.8  
Synaptic vesicle membrane protein VAT-1 homolog;cDNA FLJ54106, 
moderately similar to Synaptic vesicle membrane protein VAT-1 
homolog (EC 1.-.-.-) 2.4  
Syntaxin-binding protein 1;Unc-18 homolog;Unc-18-1;Unc-18A;N-
Sec1;p67 2.2  
TAR DNA-binding protein 43;cDNA FLJ58188, highly similar to TAR 
DNA-binding protein 43;TAR DNA binding protein 2.3 0.4 
Testis-expressed sequence 10 protein;cDNA FLJ54377 2.2 1.8 
TOB3;ATPase family AAA domain-containing protein 3B;Putative 
uncharacterized protein ATAD3B 3  
Transcription factor p65;Nuclear factor NF-kappa-B p65 
subunit;RELA protein 10.2  
Transformer-2 protein homolog alpha;TRA-2 alpha;Transformer-2 
protein homolog A 2 1.0 
Translational activator GCN1;GCN1-like protein 1 2.2 1.0 
Transmembrane protein 165;Transmembrane protein 
TPARL;Transmembrane protein PT27 3  
Transmembrane protein 49;Vacuole membrane protein 1 2.1  
U1 small nuclear ribonucleoprotein 70 kDa 2 1.5 
Ubiquitin-conjugating enzyme E2 variant 1;CROC-1;TRAF6-regulated 
IKK activator 1 beta Uev1A;Ubiquitin-conjugating enzyme E2 variant 
2;MMS2;Enterocyte differentiation-associated factor EDAF-
1;Enterocyte differentiation-promoting factor;EDPF-1;Vitamin D3-
inducible protein;DDVit 1 4.1 5.4 
Up-regulated during skeletal muscle growth protein 5;HCV F-
transactivated protein 2 5.4  
Vimentin 2.3 1.4 
Voltage-dependent anion-selective channel protein 2;Outer 
mitochondrial membrane protein porin 2;Putative uncharacterized 
protein ENSP00000367226;Voltage-dependent anion channel 2 2.1 0.8 
Vomeronasal type-1 receptor 5;V1r-like receptor 5 4.4  
V-set and immunoglobulin domain-containing protein 8 7.8  
Zyxin;Zyxin-2;cDNA FLJ53160, highly similar to Zyxin 2  
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APPENDIX B. TABLE OF DOWNREGULATED PROTEINS FROM 
QUANTITATIVE PROTEOMICS 
 
Protein Name 
Ratio 
(S/C) S.D. 
1,4-alpha-glucan-branching enzyme;Glycogen-branching 
enzyme;Brancher enzyme 0.5  
6-phosphofructokinase type C;Phosphofructokinase 
1;Phosphohexokinase;Phosphofructo-1-kinase isozyme C;6-
phosphofructokinase, platelet type;cDNA FLJ35278 fis, clone 
PROST2006579, highly similar to 6-phosphofructokinase type C (EC 
2.7.1.11) 0.5 0.1 
Adipophilin;Adipose differentiation-related protein;cDNA FLJ59123, 
moderately similar to Adipophilin 0.2  
Beta-enolase;2-phospho-D-glycerate hydro-lyase;Muscle-specific 
enolase;Skeletal muscle enolase;Enolase 3;Enolase 0.4  
cDNA, FLJ92861, highly similar to Homo sapiens serine (or cysteine) 
proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 
1), member 2 (SERPINE2), mRNA;Glia-derived nexin;Protease nexin 
I;PN-1;Protease inhibitor 7;cDNA FLJ51896, highly similar to Glia-derived 
nexin 0.3  
ERO1-like protein alpha;Oxidoreductin-1-L-alpha;Endoplasmic 
oxidoreductin-1-like protein;Putative uncharacterized protein ERO1L 0.4 0.0 
Eukaryotic translation initiation factor 4H;Williams-Beuren syndrome 
chromosomal region 1 protein 0.5  
Gamma-enolase;2-phospho-D-glycerate hydro-lyase;Neural 
enolase;Neuron-specific enolase;Enolase 2 0.4 0.1 
Glyceraldehyde-3-phosphate dehydrogenase;Glyceraldehyde 3-
phosphate dehydrogenase 0.5  
Glycogen phosphorylase, liver form 0.5  
Interferon-induced transmembrane protein 3;Interferon-inducible protein 
1-8U;Interferon-induced transmembrane protein 2;Interferon-inducible 
protein 1-8D;IFITM2 protein;Interferon-induced transmembrane protein 
1;Interferon-inducible protein 9-27;Interferon-induced protein 17;Leu-13 
antigen;Putative uncharacterized protein IFITM1 0.5  
L-lactate dehydrogenase A chain;LDH muscle subunit;Renal carcinoma 
antigen NY-REN-59;Cell proliferation-inducing gene 19 protein;L-lactate 
dehydrogenase 0.5 0.1 
L-lactate dehydrogenase A-like 6B 0.4  
Melanoma-associated antigen B6;MAGE-B6 antigen;Cancer/testis 
antigen 3.4 0.1  
Mothers against decapentaplegic homolog 2;Mad-related protein 2;SMAD 
2;hSMAD2;JV18-1;Mothers against decapentaplegic homolog 3;SMAD 
3;hSMAD3;JV15-2 0.4  
MSTP157 0.4  
Paladin 0.03  
Phosphoglycerate kinase 1;Primer recognition protein 2;Cell migration-
inducing gene 10 protein;Phosphoglycerate kinase 0.5 0.0 
Pre-mRNA-processing-splicing factor 8;Splicing factor Prp8;PRP8 
homolog;220 kDa U5 snRNP-specific protein;p220 0.3  
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1;Lysyl hydroxylase 
1;cDNA FLJ53377, highly similar to Procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 1 (EC 1.14.11.4) 0.5 0.2 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2;Lysyl hydroxylase 2 0.5 0.1 
Prolyl 4-hydroxylase subunit alpha-1;4-PH alpha-1;Procollagen-proline,2-
oxoglutarate-4-dioxygenase subunit alpha-1 0.5 0.2 
Prostaglandin G/H synthase 1;Cyclooxygenase-1;Prostaglandin-
endoperoxide synthase 1;Prostaglandin H2 synthase 1 0.5 0.3 
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Protein NDRG1;N-myc downstream-regulated gene 1 
protein;Differentiation-related gene 1 protein;Reducing agents and 
tunicamycin-responsive protein;Nickel-specific induction protein 
Cap43;Rit42;cDNA FLJ39243 fis, clone OCBBF2008283, highly similar to 
Protein NDRG1 0.4  
Protein-L-isoaspartate(D-aspartate) O-methyltransferase;Protein-beta-
aspartate methyltransferase;Protein L-isoaspartyl/D-aspartyl 
methyltransferase;L-isoaspartyl protein carboxyl methyltransferase 0.4  
Retinoic acid-induced protein 3;G-protein coupled receptor family C group 
5 member A;Retinoic acid-induced gene 1 protein;Orphan G-protein-
coupling receptor PEIG-1 0.5  
RNA binding protein (Autoantigenic, hnRNP-associated with lethal yellow) 
long isoform variant;RNA binding protein, autoantigenic (HnRNP-
associated with lethal yellow homolog (Mouse));cDNA FLJ77422, highly 
similar to Homo sapiens RNA binding protein, autoantigenic (hnRNP-
associated with lethal yellow homolog (mouse)), transcript variant 1, 
mRNA;RNA binding protein, autoantigenic (HnRNP-associated with lethal 
yellow homolog (Mouse)), isoform CRA_a;RNA-binding protein 
Raly;hnRNP associated with lethal yellow homolog;Autoantigen 
p542;Heterogeneous nuclear ribonucleoprotein C-like 2 0.5  
Solute carrier family 2, facilitated glucose transporter member 1;Glucose 
transporter type 1, erythrocyte/brain;HepG2 glucose transporter;Putative 
uncharacterized protein SLC2A1;cDNA FLJ55703, highly similar to Solute 
carrier family 2, facilitated glucose transporter member 1 0.5 0.1 
UPF0389 protein FAM162A;E2-induced gene 5 protein;DC16;cDNA 
FLJ59673, highly similar to Homo sapiens growth and transformation-
dependent protein (E2IG5), mRNA 0.3  
Vitamin K epoxide reductase complex subunit 1;Vitamin K1 2,3-epoxide 
reductase subunit 1;Putative uncharacterized protein VKORC1;Vitamin K 
epoxide reductase complex, subunit 1, isoform CRA_c;cDNA FLJ76521, 
highly similar to Homo sapiens vitamin K epoxide reductase complex, 
subunit 1 (VKORC1), transcript variant 2, mRNA 0.4  
von Willebrand factor;von Willebrand antigen 2;von Willebrand antigen 
II;cDNA FLJ59036, highly similar to von Willebrand factor 0.3  
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APPENDIX C. COMPILATION OF PROTEINS IDENTIFIED WITHOUT 
SIGNIFICANT EXPRESSION LEVEL CHANGES 
 
 
The supplemental file APPENDIX 3.xls contains the processed data for the identified 
proteins without significant changes of protein expression level from both nuclear and 
cytosolic fractions. 
 
 
 
 
 
 
